<SEC-DOCUMENT>0001213900-25-053607.txt : 20250612
<SEC-HEADER>0001213900-25-053607.hdr.sgml : 20250612
<ACCEPTANCE-DATETIME>20250612084529
ACCESSION NUMBER:		0001213900-25-053607
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		21
CONFORMED PERIOD OF REPORT:	20250609
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250612
DATE AS OF CHANGE:		20250612

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Citius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001506251
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				273425913
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38174
		FILM NUMBER:		251041756

	BUSINESS ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016
		BUSINESS PHONE:		(908) 967-6676

	MAIL ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trail One, Inc.
		DATE OF NAME CHANGE:	20110314

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrailOne, Inc.
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0245241-8k_citius.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:CTXR="http://citiuspharma.com/20250609">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_CTXR_citiuspharma.com_20250609 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20250609_20250609 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0001506251 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-06-09" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-06-09" id="Fact000004" name="dei:EntityCentralIndexKey">0001506251</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ctxr-20250609.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-06-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506251</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-09</xbrli:startDate>
        <xbrli:endDate>2025-06-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90F_edei--DocumentType_c20250609__20250609_zoQ8uqSarAo6"><ix:nonNumeric contextRef="AsOf2025-06-09" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">the Securities Exchange Act of 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported)
<span style="text-decoration: underline"><span id="xdx_905_edei--DocumentPeriodEndDate_c20250609__20250609_z5OCi3fnDpM1"><ix:nonNumeric contextRef="AsOf2025-06-09" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">June 9, 2025</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_907_edei--EntityRegistrantName_c20250609__20250609_zpA4mzMQ7091"><ix:nonNumeric contextRef="AsOf2025-06-09" id="Fact000011" name="dei:EntityRegistrantName">Citius Pharmaceuticals, Inc.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-decoration: underline"><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20250609__20250609_zwcNavk14LUa"><ix:nonNumeric contextRef="AsOf2025-06-09" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of incorporation)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 49%"><span style="font-size: 10pt"><span id="xdx_906_edei--EntityFileNumber_c20250609__20250609_z6VHM9suak78"><ix:nonNumeric contextRef="AsOf2025-06-09" id="Fact000013" name="dei:EntityFileNumber">001-38174</ix:nonNumeric></span></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 49%"><span style="font-size: 10pt"><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20250609__20250609_zZgUeldXByR7"><ix:nonNumeric contextRef="AsOf2025-06-09" id="Fact000014" name="dei:EntityTaxIdentificationNumber">27-3425913</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(IRS Employer <br/>
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 49%"><span style="font-size: 10pt"><span id="xdx_902_edei--EntityAddressAddressLine1_c20250609__20250609_z2hlxEz65Gy"><ix:nonNumeric contextRef="AsOf2025-06-09" id="Fact000015" name="dei:EntityAddressAddressLine1">11 Commerce Drive</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressAddressLine2_c20250609__20250609_z0R0A8w1mdXh"><ix:nonNumeric contextRef="AsOf2025-06-09" id="Fact000016" name="dei:EntityAddressAddressLine2">1st Floor</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressCityOrTown_c20250609__20250609_zhHHUGwDdjWc"><ix:nonNumeric contextRef="AsOf2025-06-09" id="Fact000017" name="dei:EntityAddressCityOrTown">Cranford</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20250609__20250609_zdxW0WKIyv0a"><ix:nonNumeric contextRef="AsOf2025-06-09" id="Fact000018" name="dei:EntityAddressStateOrProvince">NJ</ix:nonNumeric></span></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 49%"><span style="font-size: 10pt"><span id="xdx_901_edei--EntityAddressPostalZipCode_c20250609__20250609_zyjrc8dhvkud"><ix:nonNumeric contextRef="AsOf2025-06-09" id="Fact000019" name="dei:EntityAddressPostalZipCode">07016</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(Address of principal executive offices)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code <span style="text-decoration: underline">(<span id="xdx_907_edei--CityAreaCode_c20250609__20250609_zKLGcG7tvmnf"><ix:nonNumeric contextRef="AsOf2025-06-09" id="Fact000020" name="dei:CityAreaCode">908</ix:nonNumeric></span>) <span id="xdx_900_edei--LocalPhoneNumber_c20250609__20250609_zzXFatGeya53"><ix:nonNumeric contextRef="AsOf2025-06-09" id="Fact000021" name="dei:LocalPhoneNumber">967-6677</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--WrittenCommunications_c20250609__20250609_zVawOtlinUA9"><ix:nonNumeric contextRef="AsOf2025-06-09" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--SolicitingMaterial_c20250609__20250609_zDbSebLVkQq5"><ix:nonNumeric contextRef="AsOf2025-06-09" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--PreCommencementTenderOffer_c20250609__20250609_zhZ875nZo2rc"><ix:nonNumeric contextRef="AsOf2025-06-09" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--PreCommencementIssuerTenderOffer_c20250609__20250609_zugbEfpfAUhg"><ix:nonNumeric contextRef="AsOf2025-06-09" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_907_edei--Security12bTitle_c20250609__20250609_z0CiasunF58"><ix:nonNumeric contextRef="AsOf2025-06-09" id="Fact000026" name="dei:Security12bTitle">Common stock, $0.001 par value</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90F_edei--TradingSymbol_c20250609__20250609_zCFwvUZ5H1Fd"><ix:nonNumeric contextRef="AsOf2025-06-09" id="Fact000027" name="dei:TradingSymbol">CTXR</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The <span id="xdx_905_edei--SecurityExchangeName_c20250609__20250609_zbEZzfUNRzLj"><ix:nonNumeric contextRef="AsOf2025-06-09" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_edei--EntityEmergingGrowthCompany_c20250609__20250609_zry8iCuWICN5"><ix:nonNumeric contextRef="AsOf2025-06-09" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01. Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 9, 2025, Citius Pharmaceuticals,
Inc. (the &#8220;Company&#8221;) entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) <span style="background-color: white">with
a certain institutional investor for the issuance and sale, in a registered direct offering by the Company (the &#8220;Offering&#8221;),
of 540,000 shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Shares&#8221;), and pre-funded warrants
to purchase up to 4,380,000 shares of common stock (the &#8220;Pre-funded Warrants&#8221;) at an offering price of $1.22 and $1.2199,
respectively. The Company also issued to the investor warrants to purchase up to 9,840,000 shares of common stock (the &#8220;Warrants&#8221;).
The Offering closed on June 11, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
Warrants have an exercise price equal to $1.00 per share, are exercisable immediately upon issuance and will expire twenty-four months
after the initial exercise date.&#160;The exercise price and number of shares of common stock issuable upon exercise are subject to appropriate
adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the common stock and the exercise
price. If there is no effective registration statement for the resale of the shares issuable upon exercise of the Warrants, holders of
Warrants may elect a &#8220;cashless&#8221; exercise, whereby they would receive the net number of shares of common stock determined according
to a formula set forth in the Warrants. On the expiration date of the Warrants, any Warrants outstanding and unexercised will be automatically
exercised via cashless exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
Pre-funded Warrants are exercisable immediately, at an exercise price of $0.0001 per share, and will remain valid and exercisable until
all the Pre-funded Warrants are exercised in full. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">A
holder of a Warrant or a Pre-funded Warrant will not have the right to exercise any portion of its warrants if the holder, together with
its affiliates, would beneficially own in excess of 4.99% (or 9.99% at the election of the holder prior to the date of issuance) of the
number of shares of common stock outstanding immediately after giving effect to such exercise (the &#8220;Beneficial Ownership Limitation&#8221;);
provided, however, that upon 61 days&#8217; prior notice to the Company, the holder may increase or decrease the Beneficial Ownership
Limitation, provided that in no event shall the Beneficial Ownership Limitation exceed 9.99%. </span>The exercise price and number of
shares of common stock issuable upon exercise are subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations
or similar events affecting the common stock and the exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">H.C. Wainwright and Co., LLC
(&#8220;Wainwright&#8221;)&#160;acted as the Company&#8217;s exclusive placement agent in connection with the Offering. In connection
with the Offering, the Company agreed to pay Wainwright a cash fee of 7.0% of the gross proceeds the Company received in the Offering.
The Company agreed to also reimburse Wainwright up to $50,000 for fees and expenses of legal counsel, $35,000 for non-accountable expenses
and $15,950 for a clearing fee. In addition, the Company granted placement agent warrants to Wainwright, or its designees, to purchase
up to 344,400 shares of  common stock (the &#8220;Placement Agent Warrants&#8221;). The terms of the Placement Agent Warrants are substantially
the same as the terms of the Warrants, except that the exercise price is $1.525 per share.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
gross proceeds to the Company from the Offering were approximately $6.0 million. Net proceeds are expected to be approximately $5,455,000,
after deducting placement agent fees and other offering expenses payable by the Company. The Company anticipates using the net proceeds
to support the commercial launch of LYMPHIR&#8482;, including milestone, regulatory and other payments, and general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the Purchase Agreement, the Company agreed for a period of 60 days following the closing of the Offering not to issue, enter into an
agreement to issue or announce the issuance or proposed issuance of the shares or any other securities convertible into, or exercisable
or exchangeable for, shares of common stock, subject to certain exceptions; provided that after 30 days after the closing, the Company
may issue shares of common stock in an &#8220;at the market&#8221; offering with Wainwright as sales agent at an offering price
equal to or greater than $1.75 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Offering was made pursuant to the Company&#8217;s effective registration statement on Form S-3 (File No. 333-277319), which was previously
declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 1, 2024, including a prospectus supplement
filed with the SEC on June 11, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Purchase Agreement contains customary representations and warranties and agreements of the Company and the investor and customary indemnification
rights and obligations of the parties. The representations, warranties and covenants contained in the Purchase Agreement were made solely
for the benefit of the parties to the Purchase Agreement and may be subject to limitations agreed upon by the contracting parties. Accordingly,
the Purchase Agreement is incorporated herein by reference only to provide investors with information regarding the terms of the Purchase
Agreement, and not to provide investors with any other factual information regarding the Company or its business, and should be read in
conjunction with the disclosures in the Company&#8217;s periodic reports and other filings with the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The foregoing
descriptions of the Purchase Agreement, the Warrants, the Pre-funded Warrants and the Placement Agent Warrants are qualified in their
entirety by reference to the forms of the Purchase Agreement, the Warrants, the Pre-funded Warrants and the Placement Agent Warrants,
copies of which are attached hereto as Exhibits 10.1, 4.1, 4.2 and 4.3, respectively, and are incorporated herein by reference. A copy
of the opinion of Wyrick Robbins Yates &amp; Ponton LLP relating to the legality of the issuance and sale of the Shares, the Pre-funded
Warrants, the Warrants and the Placement Agent Warrants in the Offering is attached as Exhibit 5.1 hereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item. 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 10, 2025, the Company
issued a press release to announce the entry into the Purchase Agreement. On June 12, 2025, the Company issued a press release to announce
the closing of the Offering. The press releases are attached hereto as Exhibit 99.1 and 99.2, respectively, and are incorporated herein
by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(d) The following exhibits are being
filed with this Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: justify; width: 9%"><span style="font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify; width: 90%"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea024524101ex4-1_citius.htm">Form of Warrant issued on June 11, 2025.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea024524101ex4-2_citius.htm">Form of Pre-funded Warrant issued on June 11, 2025.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea024524101ex4-3_citius.htm">Form of Placement Agent Warrant issued on June 11, 2025.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">5.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea024524101ex5-1_citius.htm">Opinion of Wyrick Robbins Yates &amp; Ponton LLP.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea024524101ex10-1_citius.htm">Form of Securities Purchase Agreement, dated as of June 9, 2025, by and among Citius Pharmaceuticals, Inc. and the investor signatory thereto.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">23.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea024524101ex5-1_citius.htm">Consent of Wyrick Robbins Yates &amp; Ponton LLP (included in Exhibit 5.1).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">99.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea024524101ex99-1_citius.htm">Press release, dated June 10, 2025.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">99.2</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea024524101ex99-2_citius.htm" style="-sec-extract: exhibit">Press release, dated June 12, 2025.</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Cover Page Interactive Date File (embedded within the Inline XBRL document).</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="text-align: justify; width: 40%"><span style="font-size: 10pt"><b>CITIUS PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">Date: June 12, 2025</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">/s/ Leonard Mazur</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Leonard Mazur</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td><span style="font-size: 10pt">Chairman and Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></span></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6La4d6sUuHSrilDGGeFtclOLWjLT+7JF8S+uGGAIhOefLEWIiNrQ2DTKclmUOFbZdoz1CiRdktGcMjmy7SyHMEq/GedbWD+sPzCgwGJjFVJ7DfXA+jMM6BbmIlYyTOchZqhQUexF99YzsxdRovdENaFtDwdSxQa+5Hz9U+kWW2n5IOiI7QzYFNZWj/IZEqgQO9NBP4puDPM9ENBkqEhumexdcq5dH+yVh1WAb4txI/zv6AMc8SlU= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ea024524101ex4-1_citius.htm
<DESCRIPTION>FORM OF WARRANT ISSUED ON JUNE 11, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Citius
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">Warrant Shares: _______</TD>
    <TD STYLE="text-align: right; width: 50%; font-size: 10pt; vertical-align: bottom">Initial Exercise Date: June 11, 2025</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">THIS COMMON STOCK PURCHASE
WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on June 11, 2027
(the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Citius Pharmaceuticals, Inc., a Nevada
corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;)
of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined
in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;Purchase Agreement&rdquo;), dated June 9, 2025, among the Company and the purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;<U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank
unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this
Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised
in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the
date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a
portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise on the Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant,
acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares
hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the
face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;<U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$1.00</B>, subject to adjustment hereunder (the
&ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;<U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in
part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(A)</TD>
    <TD STYLE="width: 0.25in">=</TD><TD STYLE="text-align: justify"> as applicable: (i) the VWAP on the Trading Day immediately
preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section
2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior
to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities
laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of
the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P.
as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular
trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close
of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable
Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered
pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(B)</TD>
    <TD STYLE="width: 0.25in">=</TD><TD STYLE="text-align: justify"> the Exercise Price of this Warrant, as adjusted hereunder;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 1in">&nbsp;</TD>
<TD STYLE="width: 0.25in">(X)</TD><TD STYLE="width: 0.25in; text-align: left">=</TD><TD STYLE="text-align: justify"> the number of Warrant Shares that would be issuable upon
exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a
cashless exercise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white"><U>&ldquo;Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock
so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;<U>VWAP</U>&rdquo;
</FONT>means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock
is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the <FONT STYLE="background-color: white">Purchasers</FONT> of a majority in interest of the Securities then
outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp;The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;<U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.&nbsp;<U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system
and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate,
registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which
the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is
the earlier of (i) one (1) Trading Day and (ii) the number of days comprising the Standard Settlement Period, in each case after the delivery
to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice
of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect
to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate
Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the Company fails for
any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company
shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise
(based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading
Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date
until such Warrant Shares are delivered or the Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is
a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement
Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading
Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing,
with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which
may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant Shares subject
to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share
Delivery Date for purposes hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.&nbsp;<U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.&nbsp;<U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.&nbsp;<U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its
broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise
(a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.&nbsp;<U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.&nbsp;<U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.&nbsp;<U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;<U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial
ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder,
it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section
13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the
extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any
group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may
rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report
filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice
by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request
of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall
be [4.99%] [9.99%] of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership
Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this
Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation
will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;<U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)&nbsp;</FONT><U>Reserved</U>.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder&rsquo;s right
to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall
not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result
of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time,
if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;<U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>,
to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of
any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;<U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one
or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company
or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other
securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding Common Stock or greater than
50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly,
in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires greater than 50% of the outstanding shares of Common Stock or greater than 50% of the voting power
of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this
Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e)
on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if
it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result
of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately
prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the
Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any
different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property
to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives
upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a
Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any
time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public
announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash
equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental
Transaction; <U>provided</U>, <U>however</U>, if the Fundamental Transaction is not within the Company&rsquo;s control, including not approved
by the Company&rsquo;s Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity, as of the
date of consummation of such Fundamental Transaction, the same type or form of consideration (and in the same proportion), at the Black
Scholes Value (as defined below) of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock
of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination
thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection
with the Fundamental Transaction; <U>provided</U>, <U>further</U>, that if holders of Common Stock of the Company are not offered or paid
any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor
Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black
Scholes Value</U>&rdquo; means the value of this Warrant based on the Black Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo;
function on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) determined as of the day of consummation of the applicable Fundamental Transaction
for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time
between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected
volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a
365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental
Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being
offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii)
the highest VWAP during the period beginning on the Trading Day immediately preceding the announcement of the applicable contemplated
Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the
Holder&rsquo;s request pursuant to this Section 3(e) and (D) a remaining option time equal to the time between the date of the public
announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment
of the Black Scholes Value will be made by wire transfer of immediately available funds (or by delivery of such other consideration, as
applicable) within five Business Days of the Holder&rsquo;s election (or, if later, on the consummation date of the Fundamental Transaction).&nbsp;
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor
Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of
this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder
(without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange
for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this
Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent
to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise
of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such
shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction
and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of
protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably
satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall
succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring
to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall
assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the
Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(e) regardless
of (i) whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental
Transaction occurs prior to the Initial Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)&nbsp;<U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)&nbsp;<U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.&nbsp;<U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.&nbsp;<U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of
the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property,
or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company,
then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;<U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this
Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any
transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;<U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with
this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;<U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;<U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set
forth in Section 3. Without limiting the rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise,&rdquo; and to receive
the cash payments contemplated pursuant to Sections 2(d)(i) and 2(d)(iv), in no event will the Company be required to net cash settle
a Warrant exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;<U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;<U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;<U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;<U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed
and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflict of laws thereof.
Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense of this Warrant shall be commenced
in the state and federal courts sitting in the City of New York, Borough of Manhattan (the &ldquo;<U>New York Courts</U>&rdquo;). Each
party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not
to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such New York Courts,
or such New York Courts are improper or inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service
of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified
mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and
agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be
deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action,
suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed
by the other party for their reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation
and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)&nbsp;<U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)&nbsp;<U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts
due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)&nbsp;<U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice
of Exercise, shall be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally recognized overnight courier
service, addressed to the Company at 11 Commerce Drive, First Floor, Cranford, New Jersey 07016, Attention: <B>Jamie Bartushak, Chief
Financial Officer</B>, email address: <B>jbartushak@citiuspharma.com</B>, or such other facsimile number, email address or address as
the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided
by the Company hereunder shall be in writing and delivered personally, by facsimile or email, or sent by a nationally recognized overnight
courier service addressed to each Holder at the facsimile number, email address or address of such Holder appearing on the books of the
Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time
of transmission, if such notice or communication is delivered via facsimile or email at the facsimile number or email address set forth
in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the date of transmission, if such
notice or communication is delivered via facsimile or email at the facsimile number or email address set forth in this Section on a day
that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the
date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such
notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information
regarding the Company or any subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current
Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)&nbsp;<U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)&nbsp;<U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)&nbsp;<U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)&nbsp;<U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)&nbsp;<U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)&nbsp;<U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Citius Pharmaceuticals, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:&nbsp;</TD>
    <TD STYLE="width: 31%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase">To:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase">Citius Pharmaceuticals,
Inc.</FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)&nbsp;The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)&nbsp;Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&#9744; in
lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&#9744; if
permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise
procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)&nbsp;Please issue said
Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the
following DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: left">Name:</TD>
    <TD STYLE="width: 2%; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 49%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Address:</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Phone Number:</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Email Address:</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Dated: _______________ __, ______</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Holder&rsquo;s Signature: ___________________________</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Holder&rsquo;s Address:  _____________________________</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>ea024524101ex4-2_citius.htm
<DESCRIPTION>FORM OF PRE-FUNDED WARRANT ISSUED ON JUNE 11, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.2&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRE-FUNDED COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Citius
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%">Warrant Shares: _______</TD><TD STYLE="width: 50%; text-align: right">Initial Exercise Date: June 11, 2025&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS PRE-FUNDED COMMON STOCK
PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date set forth above (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) until this Warrant is exercised in full (the &ldquo;<U>Termination
Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Citius Pharmaceuticals, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;),
up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price
of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;Purchase Agreement&rdquo;), dated June 9, 2025, among the Company and the purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)   <U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within
the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section
2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares
specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless
exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise
shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case,
the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice
of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of
Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in
an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number
of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise on the Trading
Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of
the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)   <U>Exercise
Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.0001 per Warrant Share, was pre-funded
to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise
price of $0.0001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The
Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance
or for any reason whatsoever. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be $0.0001, subject
to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)   <U>Cashless
Exercise</U>. This Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which
the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(A)</TD>
    <TD STYLE="text-align: center; width: 0.25in">=</TD><TD STYLE="text-align: justify"> as applicable: (i) the VWAP on the Trading Day immediately
preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section
2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior
to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities
laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of
the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P.
as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular
trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close
of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable
Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered
pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(B)</TD>
    <TD STYLE="text-align: center; width: 0.25in">= </TD><TD STYLE="text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(X)</TD>
    <TD STYLE="text-align: center; width: 0.25in">=</TD><TD STYLE="text-align: justify"> the number of Warrant Shares that would be issuable upon exercise
of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless
exercise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white"><U>&ldquo;Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock
so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;<U>VWAP</U>&rdquo;
</FONT>means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock
is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the <FONT STYLE="background-color: white">Purchasers</FONT> of a majority in interest of the Securities then
outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)   <U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.   <U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system
and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate,
registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which
the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is
the earlier of (i) one (1) Trading Day and (ii) the number of days comprising the Standard Settlement Period, in each case after the delivery
to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice
of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect
to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate
Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the Company fails for
any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company
shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise
(based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading
Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date
until such Warrant Shares are delivered or the Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is
a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement
Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading
Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing,
with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which
may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant Shares subject
to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share
Delivery Date for purposes hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.   <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.   <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.   <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its
broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise
(a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.   <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.   <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.   <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)   <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial
ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder,
it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section
13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the
extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any
group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may
rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report
filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice
by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request
of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall
be [4.99%] [9.99%] of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership
Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this
Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation
will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)   <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)   </FONT><U>Reserved</U>.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)   <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder&rsquo;s right
to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall
not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result
of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time,
if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)   <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>,
to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of
any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)   <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one
or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company
or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other
securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding Common Stock or greater than
50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly,
in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires greater than 50% of the outstanding shares of Common Stock or greater than 50% of the voting power
of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this
Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e)
on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if
it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result
of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately
prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the
Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any
different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property
to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives
upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations
of the Company under this Warrant in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance
reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and
shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by
a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares
of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon
exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and
with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative
value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number
of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder.
Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and
after the date of such Fundamental Transaction, the provisions of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead
to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company
under this Warrant with the same effect as if such Successor Entity had been named as the Company herein. For the avoidance of doubt,
the Holder shall be entitled to the benefits of the provisions of this Section 3(e) regardless of (i) whether the Company has sufficient
authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the
Initial Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)   <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)   <U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.   <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.   <U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of
the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property,
or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company,
then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)   <U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this
Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any
transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)   <U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with
this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)   <U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)   <U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set
forth in Section 3. Without limiting the rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise,&rdquo; and to receive
the cash payments contemplated pursuant to Sections 2(d)(i) and 2(d)(iv), in no event will the Company be required to net cash settle
a Warrant exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)   <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)   <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)   <U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)   <U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed
and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflict of laws thereof.
Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense of this Warrant shall be commenced
in the state and federal courts sitting in the City of New York, Borough of Manhattan (the &ldquo;<U>New York Courts</U>&rdquo;). Each
party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not
to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such New York Courts,
or such New York Courts are improper or inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service
of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified
mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and
agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be
deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action,
suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed
by the other party for their reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation
and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)   <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)   <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts
due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)   <U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice
of Exercise, shall be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally recognized overnight courier
service, addressed to the Company at 11 Commerce Drive, First Floor, Cranford, New Jersey 07016, Attention: <B>Jamie Bartushak, Chief
Financial Officer</B>, email address: <B>jbartushak@citiuspharma.com</B>, or such other facsimile number, email address or address as
the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided
by the Company hereunder shall be in writing and delivered personally, by facsimile or email, or sent by a nationally recognized overnight
courier service addressed to each Holder at the facsimile number, email address or address of such Holder appearing on the books of the
Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time
of transmission, if such notice or communication is delivered via facsimile or email at the facsimile number or email address set forth
in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the date of transmission, if such
notice or communication is delivered via facsimile or email at the facsimile number or email address set forth in this Section on a day
that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the
date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such
notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information
regarding the Company or any subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current
Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)   <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)   <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)   <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)   <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)   <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)   <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Citius Pharmaceuticals, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:&nbsp;</TD>
    <TD STYLE="width: 31%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"><FONT STYLE="text-transform: uppercase">To:</FONT></TD><TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase">Citius Pharmaceuticals,
Inc.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)   The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)   Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&#9744; in
lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&#9744; if
permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise
procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)   Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: left">Name:</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 49%; text-align: left"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Address:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Phone Number:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Email Address:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Dated: _________________________________,</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Holder&rsquo;s Signature: ________________________</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Holder&rsquo;s Address: _________________________</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>ea024524101ex4-3_citius.htm
<DESCRIPTION>FORM OF PLACEMENT AGENT WARRANT ISSUED ON JUNE 11, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 4.3</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Citius
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">Warrant Shares: _______</TD>
    <TD STYLE="width: 50%; font-size: 10pt">Initial Exercise Date: June 11, 2025</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS PLACEMENT AGENT COMMON
STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on June 11, 2027 (the
&ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Citius Pharmaceuticals, Inc., a Nevada corporation
(the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;)
of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in
Section 2(b). This Warrant is issued pursuant to that certain Engagement Agreement, by and between the Company and H.C. Wainwright &amp;
Co., LLC, dated as of April 10, 2024, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;Purchase Agreement&rdquo;), dated June 9, 2025, among the Company and the purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within
the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section
2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares
specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless
exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise
shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case,
the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice
of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of
Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in
an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number
of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise on the Trading
Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of
the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$1.525</B>, subject to adjustment hereunder (the
&ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in
part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 28pt">(A) =</TD><TD STYLE="text-align: justify">as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice
of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading
Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading
hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at
the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or
(z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a
Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading
hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the
date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof
after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 28pt">(B) =</TD><TD STYLE="text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 28pt">(X) =</TD><TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the
terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the
Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;<U>VWAP</U>&rdquo;
</FONT>means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock
is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the <FONT STYLE="background-color: white">Purchasers</FONT> of a majority in interest of the Securities then
outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp;&nbsp;The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system
and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate,
registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which
the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is
the earlier of (i) one (1) Trading Day and (ii) the number of days comprising the Standard Settlement Period, in each case after the delivery
to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice
of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect
to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate
Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the Company fails for
any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company
shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise
(based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading
Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date
until such Warrant Shares are delivered or the Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is
a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement
Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading
Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing,
with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which
may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant Shares subject
to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share
Delivery Date for purposes hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its
broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise
(a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v. <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii. <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial
ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder,
it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section
13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the
extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any
group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may
rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report
filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice
by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request
of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall
be 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation
provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of
the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held
by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will
not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be
construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b) </FONT><U>Reserved</U>.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder&rsquo;s right
to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall
not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result
of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time,
if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise, other
than cash (including, without limitation, any distribution of stock or other securities, property or options by way of a dividend, spin
off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the
beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one
or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company
or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other
securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding Common Stock or greater than
50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly,
in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires greater than 50% of the outstanding shares of Common Stock or greater than 50% of the voting power
of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this
Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e)
on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if
it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result
of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately
prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the
Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any
different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property
to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives
upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a
Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any
time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public
announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash
equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental
Transaction; <U>provided</U>, <U>however</U>, if the Fundamental Transaction is not within the Company&rsquo;s control, including not
approved by the Company&rsquo;s Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity,
as of the date of consummation of such Fundamental Transaction, the same type or form of consideration (and in the same proportion), at
the Black Scholes Value (as defined below) of the unexercised portion of this Warrant, that is being offered and paid to the holders of
Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or
any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration
in connection with the Fundamental Transaction; <U>provided</U>, <U>further</U>, that if holders of Common Stock of the Company are not
offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common
stock of the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.
&ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Warrant based on the Black Scholes Option Pricing Model obtained from
the &ldquo;OV&rdquo; function on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) determined as of the day of consummation of the applicable
Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for
a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the
Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on
Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of
the applicable contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater
of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered
in such Fundamental Transaction and (ii) the highest VWAP during the period beginning on the Trading Day immediately preceding the announcement
of the applicable contemplated Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and
ending on the Trading Day of the Holder&rsquo;s request pursuant to this Section 3(e) and (D) a remaining option time equal to the time
between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E) a
zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or by delivery
of such other consideration, as applicable) within five Business Days of the Holder&rsquo;s election (or, if later, on the consummation
date of the Fundamental Transaction).&nbsp; The Company shall cause any successor entity in a Fundamental Transaction in which the Company
is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this
Warrant in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory
to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of
the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor
Entity had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions
of this Section 3(e) regardless of (i) whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant
Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of
the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property,
or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company,
then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this
Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any
transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with
this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set
forth in Section 3. Without limiting the rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise,&rdquo; and to receive
the cash payments contemplated pursuant to Sections 2(d)(i) and 2(d)(iv), in no event will the Company be required to net cash settle
a Warrant exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed
and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflict of laws thereof.
Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense of this Warrant shall be commenced
in the state and federal courts sitting in the City of New York, Borough of Manhattan (the &ldquo;<U>New York Courts</U>&rdquo;). Each
party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not
to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such New York Courts,
or such New York Courts are improper or inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service
of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified
mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and
agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be
deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action,
suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed
by the other party for their reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation
and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts
due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h) <U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice
of Exercise, shall be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally recognized overnight courier
service, addressed to the Company at 11 Commerce Drive, First Floor, Cranford, New Jersey 07016, Attention: <B>Jamie Bartushak, Chief
Financial Officer</B>, email address: <B>jbartushak@citiuspharma.com</B>, or such other facsimile number, email address or address as
the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided
by the Company hereunder shall be in writing and delivered personally, by facsimile or email, or sent by a nationally recognized overnight
courier service addressed to each Holder at the facsimile number, email address or address of such Holder appearing on the books of the
Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time
of transmission, if such notice or communication is delivered via facsimile or email at the facsimile number or email address set forth
in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the date of transmission, if such
notice or communication is delivered via facsimile or email at the facsimile number or email address set forth in this Section on a day
that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the
date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such
notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information
regarding the Company or any subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current
Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Citius Pharmaceuticals, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To: Citius
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2) Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&#9744; in
lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&#9744; if permitted the
cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise
this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in
subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3) Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"> <B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; text-align: justify">Name:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 45%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(Please Print)</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(Please Print)</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Phone Number:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Email Address: </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Dated: _______________ __, ______</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Holder&rsquo;s Signature: ______________________</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Holder&rsquo;s Address: _______________________</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>ea024524101ex5-1_citius.htm
<DESCRIPTION>OPINION OF WYRICK ROBBINS YATES & PONTON LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Wyrick Robbins Yates &amp; Ponton LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">4101 Lake Boone Trail, Suite 300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Raleigh, North Carolina 27607-7506</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">June 11, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Citius Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11 Commerce Drive, First Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cranford, New Jersey 07016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as counsel to
Citius Pharmaceuticals, Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), in connection with the issuance and sale of (i)
an aggregate of 540,000 shares (the &ldquo;<B>Shares</B>&rdquo;) of the Company&rsquo;s common stock, $0.001 par value per share (the
&ldquo;<B>Common Stock</B>&rdquo;), (ii) investor warrants to purchase up to 9,840,000 shares of Common Stock (the &ldquo;<B>Investor
Warrants</B>&rdquo;); (iii) <FONT STYLE="background-color: white">pre-funded warrants to purchase up to </FONT>4,380,000 <FONT STYLE="background-color: white">shares
of Common Stock (the &ldquo;<B>Pre-funded Warrants</B>&rdquo;); </FONT>and (iv) placement agent warrants to purchase up to an aggregate
of 344,400 shares of Common Stock (the &ldquo;<B>Placement Agent Warrants</B>&rdquo;), pursuant to the registration statement on Form
S-3 (Registration Statement No. 333-277319), as filed by the Company with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;)
pursuant to the Securities Act of 1933, as amended (the &ldquo;<B>Act</B>&rdquo;), as declared effective by the Commission on March 1,
2024 (the registration statement, as it may be amended from time to time, is herein referred to as the &ldquo;<B>Registration Statement</B>&rdquo;),
together with the exhibits to the Registration Statement and the documents incorporated by reference therein and the related base prospectus
which forms a part of and is included in the Registration Statement and the related prospectus supplement in the form filed with the Commission
pursuant to Rule 424(b) under the Act on June 11, 2025 (the &ldquo;<B>Prospectus</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Shares, Pre-Funded Warrants and Investor Warrants are to be sold pursuant to a Securities Purchase Agreement, dated as of June 9,
2025, by and among the Company and the investor signatory thereto (the &ldquo;Purchase Agreement&rdquo;), which has been filed as an exhibit
to the Company&rsquo;s Current Report on Form 8-K filed on June 11, 2025. The Placement Agent Warrants are to be issued pursuant to the
engagement letter agreement dated April 10, 2024, as amended on November 15, 2024, between the Company and H.C. Wainwright &amp; Co.,
LLC (the &ldquo;Placement Agent Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with this opinion,
we have examined and relied upon the Registration Statement and the Prospectus, the Company&rsquo;s Amended and Restated Articles of Incorporation,
as amended to date, the Company&rsquo;s Amended and Restated Bylaws, as amended to date, the Purchase Agreement, the Placement Agent Agreement
and such instruments, documents, certificates and records that we have deemed relevant and necessary for the basis of our opinion hereinafter
expressed. In such examination, we have assumed: (i) the authenticity of original documents and the genuineness of all signatures; (ii)
the conformity to the originals of all documents submitted to us as copies; (iii) the truth, accuracy and completeness of the information,
representations and warranties contained in the records, documents, instruments and certificates we have reviewed; and (iv) the due execution
and delivery of all documents where due execution and delivery are a prerequisite to the effectiveness thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon the foregoing,
we are of the opinion that (i) the Shares, when issued and sold in accordance with the Purchase Agreement, the Registration Statement
and the Prospectus, will be duly authorized, validly issued, fully paid and non-assessable, (ii) the Investor Warrants, when issued in
accordance with the Placement Agent Agreement, the Registration Statement and the Prospectus, will constitute valid and binding obligations
of the Company, enforceable against the Company in accordance with their terms, except as enforcement thereof may be limited by applicable
bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors&rsquo; rights, and subject to
general equity principles and to limitations on availability of equitable relief, including specific performance; (iii) the Pre-funded
Warrants, when issued in accordance with the Placement Agent Agreement, the Registration Statement and the Prospectus, will constitute
valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, except as enforcement thereof
may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors&rsquo;
rights, and subject to general equity principles and to limitations on availability of equitable relief, including specific performance,
(iv) the Placement Agent Warrants, when issued in accordance with the Placement Agent Agreement, the Registration Statement and the Prospectus,
will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, except as
enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws
affecting creditors&rsquo; rights, and subject to general equity principles and to limitations on availability of equitable relief, including
specific performance, (v) when the shares of Common Stock underlying the Investor Warrants (the &ldquo;<B>Investor Warrant Shares</B>&rdquo;)
are issued and paid for in accordance with the terms and conditions of the Purchase Agreement and the Investor Warrants and issued and
sold in accordance with the Registration Statement and the Prospectus, the Investor Warrant Shares will be duly authorized, validly issued,
fully paid and non-assessable; (vi) when the shares of Common Stock underlying the Pre-funded Warrants (the &ldquo;<B>Pre-funded Warrant
Shares</B>&rdquo;) are issued and paid for in accordance with the terms and conditions of the Purchase Agreement and the Pre-funded Warrants
and issued and sold in accordance with the Registration Statement and the Prospectus, the Pre-funded Warrant Shares will be duly authorized,
validly issued, fully paid and non-assessable, and (vii) when the shares of Common Stock underlying the Placement Agent Warrants (the
&ldquo;<B>Placement Agent Warrant Shares</B>&rdquo;) are issued and paid for in accordance with the terms and conditions of the Placement
Agent Agreement and the Placement Agent Warrants and issued and sold in accordance with the Registration Statement and the Prospectus,
the Placement Agent Warrant Shares will be duly authorized, validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">This opinion is limited to
the current federal laws of the United States and laws of the State of Nevada, including the statutory provisions and reported judicial
decisions interpreting these laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">We hereby consent to the
use of our name wherever it appears in the Registration Statement and the Prospectus, and in any amendment or supplement thereto, the
filing of this opinion as an exhibit to a current report on Form&nbsp;8-K of the Company and the incorporation by reference of this opinion
in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">In giving this consent, we
do not admit that we are within the category of persons whose consent is required by Section&nbsp;7 of the Securities Act or the rules&nbsp;and
regulations promulgated thereunder by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%; padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 40%; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Sincerely,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">/S/ WYRICK ROBBINS YATES &amp; PONTON LLP</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>6
<FILENAME>ea024524101ex10-1_citius.htm
<DESCRIPTION>FORM OF SECURITIES PURCHASE AGREEMENT, DATED AS OF JUNE 9, 2025, BY AND AMONG CITIUS PHARMACEUTICALS, INC. AND THE INVESTOR SIGNATORY THERETO
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: right; text-indent: -0.5in"><B>E<FONT STYLE="text-transform: lowercase">xhibit
10.1</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><B>SECURITIES
PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Purchase Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) is dated as of June 9, 2025, between Citius Pharmaceuticals, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;),
and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo;
and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to the terms
and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act of 1933, as amended
(the &ldquo;<U>Securities Act</U>&rdquo;), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and
not jointly, desires to purchase from the Company, Securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are
hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE I.</B><BR>
DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT> <U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following
terms have the meanings set forth in this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Acquiring Person</U>&rdquo;
shall have the meaning ascribed to such term in Section 4.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day
on which banking institutions in the State of New York are authorized or required by law or other governmental action to close; <U>provided</U>,
<U>however</U>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &ldquo;stay
at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo; or any other similar orders or restrictions or the closure
of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including
for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo;
obligations to pay the Subscription Amount and (ii) the Company&rsquo;s obligations to deliver the Securities, in each case, have been
satisfied or waived, but in no event later than the first (1st) Trading Day following the date hereof (or the second (2<SUP>nd</SUP>)
Trading Day following the date hereof if this Agreement is signed on a day that is not a Trading Day or after 4:00 p.m. (New York City
time) and before midnight (New York City time) on a Trading Day).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Warrants</U>&rdquo; means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with
Section 2.2(a) hereof, which Common Warrants shall be exercisable immediately and have a term of exercise equal to twenty-four (24) months
following the initial exercise date, in the form of <U>Exhibit A-1</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Counsel</U>&rdquo; means Wyrick Robbins Yates &amp; Ponton LLP, with offices located at 4101 Lake Boone Trail, Suite 300, Raleigh, North
Carolina 27607.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date
hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight
(New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof,
unless otherwise instructed as to an earlier time by the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers, directors, consultants or vendors
of the Company pursuant to any stock or option plan or arrangement duly adopted for such purpose, by a majority of the non-employee members
of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services
rendered to the Company, provided that such issuances to consultants and vendors are issued as &ldquo;restricted securities&rdquo; (as
defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith
within thirty (30) days following the Closing Date, (b) securities upon the exercise or exchange of or conversion of any Securities issued
hereunder, warrants to the Placement Agent in connection with the transactions pursuant to this Agreement and any securities upon exercise
of the warrants to the Placement Agent, and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock
issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement
to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other
than in connection with stock splits or combinations) or to extend the term of such securities, and (c) securities issued pursuant to
acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities
are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights that require or permit the
filing of any registration statement in connection therewith during the prohibition period in Section 4.12(a) herein, and provided that
any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating
company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional
benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily
for the purpose of raising capital or to an entity whose primary business is investing in securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>"
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per Share
Purchase Price</U>&rdquo; equals <B>$1.22</B>, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement, provided that the purchase price per Pre-Funded
Warrant shall be the Per Share Purchase Price minus $0.0001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement
Agent</U>&rdquo; means H.C. Wainwright &amp; Co., LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrants</U>&rdquo; means, collectively, the Pre-Funded Common Stock purchase warrants delivered to one or more of the Purchasers at the
Closing in accordance with Section 2.2(a)(v) hereof, in the form of <U>Exhibit A-2</U> attached hereto, which Pre-Funded Warrants shall
be exercisable immediately and will expire when exercised in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition) pending or, to the Company&rsquo;s knowledge, threatened in writing against or affecting the Company, any Subsidiary
or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority
(federal, state, county, local or foreign).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
means the final base prospectus filed for the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with the Commission
and delivered by the Company to each Purchaser prior to or at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission File No. 333-277319 which registers the sale of the Shares,
the Warrants and the Warrant Shares to the Purchasers, and includes any Rule 462(b) Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 424</U>&rdquo;
means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 462(b)
Registration Statement</U>&rdquo; means any registration statement prepared by the Company registering additional Securities, which was
filed with the Commission on or prior to the date hereof and became automatically effective pursuant to Rule 462(b) promulgated by the
Commission pursuant to the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC Reports</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Warrants and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder as specified
below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo; in
United States dollars and in immediately available funds (minus, if applicable, a Purchaser&rsquo;s aggregate exercise price of the Pre-Funded
Warrants purchased by such Purchaser, which amounts shall be paid as and when such Pre-Funded Warrants are exercised for cash).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company which is not publicly traded, as set forth in the SEC Reports, and shall, where applicable, also include
any direct or indirect subsidiary of the Company formed or acquired after the date hereof. For the avoidance of doubt, Citius Oncology,
Inc. shall not be included in the definition of Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market,
the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Warrants, all exhibits and schedules thereto and hereto and any other documents or agreements
executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means VStock Transfer, LLC, the current transfer agent of the Company, with a mailing address of 18 Lafayette Place,
Woodmere, New York 11598, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.12(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Common Warrants and the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE II.</B><BR>
PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1 Closing. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers,
severally and not jointly, agree to purchase, up to an aggregate of $6,001,962.00 of Shares, Pre-Funded Warrants and Common Warrants.
Notwithstanding anything herein to the contrary, to the extent that a Purchaser determines, in its sole discretion, that such Purchaser&rsquo;s
Subscription Amount (together with such Purchaser&rsquo;s Affiliates and any Person acting as a group together with such Purchaser or
any of such Purchaser&rsquo;s Affiliates) would cause such Purchaser&rsquo;s beneficial ownership of the shares of Common Stock to exceed
the Beneficial Ownership Limitation, such Purchaser may elect to purchase Pre-Funded Warrants in lieu of the Shares as determined pursuant
to Section 2.2(a). The &ldquo;Beneficial Ownership Limitation&rdquo; shall be 4.99% (or, at the election of the Purchaser at Closing,
9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of the Securities on the
Closing Date. Each Purchaser&rsquo;s Subscription Amount as set forth on the signature page hereto executed by such Purchaser shall be
made available for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company or its designees. The Company shall deliver to each
Purchaser its respective Shares and a Warrant as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver
the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections
2.2 and 2.3, the Closing shall occur at the offices of Company Counsel or such other location as the parties shall mutually agree. Unless
otherwise directed by the Placement Agent, settlement of the Shares shall occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;DVP&rdquo;)
(i.e., on the Closing Date, the Company shall issue the Shares registered in the Purchasers&rsquo; names and addresses and released by
the Transfer Agent directly to the account(s) at the Placement Agent identified by each Purchaser; upon receipt of such Shares, the Placement
Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement
Agent (or its clearing firm) by wire transfer to the Company). Notwithstanding anything herein to the contrary, if at any time on or after
the time of execution of this Agreement by the Company and an applicable Purchaser, through, and including the time immediately prior
to the Closing (the &ldquo;Pre-Settlement Period&rdquo;), if such Purchaser sells to any Person all, or any portion, of any Common Stock
to be issued hereunder to such Purchaser at the Closing (collectively, the &ldquo;Pre-Settlement Shares&rdquo;), such Purchaser shall,
automatically hereunder (without any additional required actions by such Purchaser or the Company), be deemed to be unconditionally bound
to purchase, and the Company shall be deemed unconditionally bound to sell, such Pre-Settlement Shares to such Purchaser at the Closing;
provided, that the Company shall not be required to deliver any Pre-Settlement Shares to such Purchaser prior to the Company&rsquo;s receipt
of the Subscription Amount for such Pre-Settlement Shares hereunder; provided, further, that the Company hereby acknowledges and agrees
that the forgoing shall not constitute a representation or covenant by such Purchaser as to whether or not such Purchaser will elect to
sell any Pre-Settlement Shares during the Pre-Settlement Period. The decision to sell any shares of Common Stock will be made in the sole
discretion of such Purchaser from time to time, including during the Pre-Settlement Period. Notwithstanding the foregoing, with respect
to any Notice(s) of Exercise (as defined in the Pre-Funded Warrants) delivered on or prior to 12:00 p.m. (New York City time) on the Closing
Date, which may be delivered at any time after the time of execution of this Agreement, the Company agrees to deliver the Warrant Shares
subject to such notice(s) by 4:00 p.m. (New York City time) on the Closing Date and the Closing Date shall be the Warrant Share Delivery
Date (as defined in the Pre-Funded Warrants) for purposes hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Deliveries</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>this Agreement duly executed by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>a legal opinion of Company Counsel, in a form reasonably acceptable to the Purchasers and the Placement Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>subject to the seventh sentence of Section 2.1, the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions,
on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>subject to the seventh sentence of Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer
Agent to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;)
Shares equal to such Purchaser&rsquo;s Subscription Amount divided by the Per Share Purchase Price (minus the number of shares of Common
Stock issuable upon exercise of such Purchaser&rsquo;s Pre-Funded Warrants, if applicable), registered in the name of such Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT> for each Purchaser of Pre-Funded Warrants pursuant to Section 2.1, a Pre-Funded Warrant registered in the name of such Purchaser
to purchase up to a number of shares of Common Stock equal to the portion of such Purchaser&rsquo;s Subscription Amount applicable to
Pre-Funded Warrants divided by the Per Share Purchase Price minus $0.0001, with an exercise price equal to $0.0001, subject to adjustment
therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>a Common Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 200% of
such Purchaser&rsquo;s Shares and Pre-Funded Warrants, with an exercise price equal to $1.00, subject to adjustment therein; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>this Agreement duly executed by such Purchaser; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>such Purchaser&rsquo;s Subscription Amount, which shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement
with the Company or its designees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Closing Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)   The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material
Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein
(unless as of a specific date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have
been performed; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being
met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material
Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained
herein (unless as of a specific date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been
performed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude
in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser,
makes it impracticable or inadvisable to purchase the Securities at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE III.</B><BR>
REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Representations and Warranties of the Company</U>. The Company hereby makes the following representations and warranties to
each Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Subsidiaries</U>. All of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports. Except as set
forth in the SEC Reports, the Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary
free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are
fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor in default of any of the provisions of its respective certificate or articles of incorporation, bylaws
or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in
good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property
owned by it makes such qualification necessary, except where the failure to be so qualified
or in good standing, as the case may be, would not have or reasonably be expected to result in: (i) a material adverse effect on the legality,
validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business,
prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect
on the Company&rsquo;s ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any
of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;); provided that a change in the market price or trading volume of
the Common Stock alone shall not be deemed, in and of itself, to constitute a Material Adverse Effect. No Proceeding has been instituted
in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate
the transactions contemplated by this Agreement and each of the other Transaction Documents to which the Company is a party and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction
Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all
necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&rsquo;s
stockholders in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction
Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance
with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in
accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents
to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and
thereby do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or
articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an
event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties
or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law,
rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company
or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company
or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as would not, individually or in the
aggregate, have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give
any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings
required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) notification(s)
to each applicable Trading Market for the listing of the Shares and Warrant Shares for trading thereon in the time and manner required
thereby, and (iv) such filings as are required to be made under applicable state securities laws (collectively, the &ldquo;<U>Required
Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Issuance of the Securities; Registration</U>. The Securities are duly authorized and, when issued and paid for in accordance
with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens
imposed by the Company. The Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid
and nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock
the maximum number of shares of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed
the Registration Statement in conformity with the requirements of the Securities Act, which became effective on March 1, 2024 (the &ldquo;<U>Effective
Date</U>&rdquo;), including the Prospectus, and such amendments and supplements thereto as may have been required prior to the date of
this Agreement. The Company was at the time of the filing of the Registration Statement eligible to use Form S-3. The Company is eligible
to use Form S-3 under the Securities Act and it meets the transaction requirements as set forth in General Instruction I.B.1 of Form S-3.
The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration
Statement or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose
have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and
regulations of the Commission, shall file the Prospectus Supplement with the Commission pursuant to Rule 424(b). At the time the Registration
Statement and any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement
and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and
will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
to make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus
or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects to the
requirements of the Securities Act and did not and will not contain
an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Capitalization</U>. The capitalization of the Company as of the dates thereof is as set forth in the SEC Reports. Except as
set forth in the SEC Reports, the Company has not issued any capital stock since its most recently filed periodic report under the Exchange
Act, other than pursuant to the exercise of employee stock options under the Company&rsquo;s stock option plans, the issuance of shares
of Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans and pursuant to the conversion and/or exercise
of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person has
any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated
by the Transaction Documents. Except as a result of the purchase and sale of the Securities and as set forth in the SEC Reports, there
are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities,
rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire,
any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which
the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital
stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common
Stock or other securities to any Person (other than the Purchasers and the Placement Agent) and will not result in a right of any holder
of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities. There are no outstanding
securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset
price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities
or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments,
understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such
Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar
plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable,
have been issued in compliance with all applicable federal and state securities laws, and none of such outstanding shares was issued in
violation of any preemptive rights or similar rights to subscribe for or purchase securities. Except for the Required Approvals, no further
approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities.
There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s capital stock
to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h) <U>SEC
Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required to
be filed by the Company under the Securities Act and Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two
years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the
foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus
and the Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or
has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such
extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities
Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact
or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under
the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material respects with
applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of
filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles
applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such
financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by
GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and
for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited
statements, to normal, immaterial, year-end audit adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements
included within the SEC Reports, except as set forth in the SEC Reports, (i) there has been no event, occurrence or development that has
had or that would reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice
and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings
made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend
or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any
shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant
to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment
of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth in the SEC Reports, no event,
liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect
to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that
would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made
that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j) <U>Litigation</U>.
Except as set forth in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or,
to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before
or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an &ldquo;<U>Action</U>&rdquo;). None of the Actions set forth in the SEC Reports, (i) adversely affects or challenges
the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) would, if there were an unfavorable
decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director
or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities
laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated,
any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission
has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary
under the Exchange Act or the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which would reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the
Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that
their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all applicable U.S. federal, state,
local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and
hours, except where the failure to be in compliance would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l) <U>Compliance</U>.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been
waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the
Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan
or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court,
arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any
governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental
protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as
would not have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Environmental Laws</U>. The Company and its Subsidiaries (i) are in compliance with all applicable federal, state, local
and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater,
land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants,
contaminants, or toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment,
or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous
Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice
letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;);
(ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i),
(ii) and (iii), the failure to so comply would be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the
appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the
SEC Reports, except where the failure to possess such permits would not reasonably be expected to result in a Material Adverse Effect
(&ldquo;<U>Material Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to
the revocation or modification of any Material Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned
by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which
is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance, except
where the failure to be in compliance would not reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(p) <U>Intellectual
Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark
applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and
similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and
which the failure to so have would have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property
Rights</U>&rdquo;). None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of,
the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned,
within two (2) years from the date of this Agreement, except where the failure to be in compliance would not reasonably be expected
to have a Material Adverse Effect. Neither the Company nor any Subsidiary has received, since the date of the latest audited
financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the
Intellectual Property Rights violate or infringe upon the rights of any Person, except as would not have or reasonably be expected
to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and
there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries
have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties,
except where failure to do so would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
The Company has no knowledge of any facts that would preclude it from having valid license rights or clear title to the Intellectual
Property Rights. The Company has no knowledge that it lacks or will be unable to obtain any rights or licenses to use all
Intellectual Property Rights that are necessary to conduct its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such
losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged,
including, but not limited to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has any reason to believe
that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from
similar insurers as may be necessary to continue its business without a significant increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Transactions With Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the officers or directors of
the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently
a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including
any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal
property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer,
director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment
of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other
employee benefits, including stock option agreements under any stock option plan of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT> <U>Sarbanes-Oxley; Internal Accounting Controls</U>. The Company and the Subsidiaries are in material compliance with any and
all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date hereof, and any and all applicable
rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The
Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions
are executed in accordance with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to
permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted
only in accordance with management&rsquo;s general or specific authorization, and (iv) the recorded accountability for assets is compared
with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the
Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company
and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company
in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified
in the Commission&rsquo;s rules and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure
controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report
under the Exchange Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic
report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures
based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over
financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or
is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Certain Fees</U>. Except for fees payable by the Company to the Placement Agent, no brokerage or finder&rsquo;s fees or commissions
are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment
banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no
obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated
in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT> <U>Registration Rights</U>. Except as set forth in the SEC Reports, no Person has any right to cause the Company or any Subsidiary
to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(w)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange
Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. Except as set forth in the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received notice
from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance
with the listing or maintenance requirements of such Trading Market. Except as set forth in the SEC Reports, the Company has no reason
to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.
The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation
and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in
connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in
order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights
agreement) or other similar anti&#45;takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents)
or the laws of its state of incorporation that is or would become applicable to the Purchasers as a result of the Purchasers and the Company
fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the
Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(y)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their
agents or counsel with any information that it believes constitutes or might constitute material, non-public information which is not
otherwise disclosed in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing
representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company
to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby is
true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to
make the statements made therein, in the light of the circumstances under which they were made, not misleading. The press releases disseminated
by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in
the light of the circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or
has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth
in Section 3.2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(z)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section
3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any
offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the
Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any
Trading Market on which any of the securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(aa)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Solvency</U>. Except as set forth in the SEC Reports, based on the consolidated financial condition of the Company as of the
Closing Date, after giving effect to the receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair
saleable value of the Company&rsquo;s assets exceeds the amount that will be required to be paid on or in respect of the Company&rsquo;s
existing debts and other liabilities (including known contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute
unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking
into account the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements
and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive,
were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts
on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability
to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). Except
as set forth in the SEC Reports, the Company has no knowledge of any facts or circumstances which lead it to believe that it will file
for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date.
The SEC Reports set forth as of the dates thereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary,
or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means
(x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary
course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or
not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto), except guaranties by
endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the
present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither
the Company nor any Subsidiary is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(bb)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result
in a Material Adverse Effect, the Company and its Subsidiaries each (i)
has made or filed all United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations
required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material
in amount, shown or determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably
adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply.
There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the
Company or of any Subsidiary know of no basis for any such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(cc)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary,
any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(dd)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Accountants</U>. The Company&rsquo;s independent registered public accounting firm is set forth in the SEC Reports. To the knowledge
and belief of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall
express its opinion with respect to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year ending
September 30, 2025. Other than permissible tax compliance services, such accounting firm has not, during the periods covered by the financial
statements included in the Prospectus, provided to the Company any non-audit services, as such term is used in Section 10A(g) of the Exchange
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ee)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT> <U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the
Purchasers is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions
contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company
(or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given
by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions
contemplated thereby is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each
Purchaser that the Company&rsquo;s decision to enter into this Agreement and the other Transaction Documents has been based solely on
the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ff) <FONT STYLE="text-decoration: none double"></FONT><FONT STYLE="text-decoration: none double"><U>Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity</U></FONT>. Anything in this Agreement or
elsewhere herein to the contrary notwithstanding (except for Sections&nbsp;3.2(f) and 4.14 hereof), it is understood and acknowledged
by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from
purchasing or selling, long and/or short, securities of the Company, or &ldquo;derivative&rdquo; securities based on securities issued
by the Company or to hold the Securities for any specified term; (ii) past or future open market or other transactions by any Purchaser,
specifically including, without limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this
or future private placement transactions, may negatively impact the market price of the Company&rsquo;s publicly-traded securities; (iii)&nbsp;any
Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to which any such Purchaser is a party, directly or indirectly,
presently may have a &ldquo;short&rdquo; position in the Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation
with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction. The Company further understands
and acknowledges that (y) one or more Purchasers may engage in hedging activities (in material compliance with applicable laws) at various
times during the period that the Securities are outstanding, including, without limitation, during the periods that the value of the
Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the
value of the existing stockholders&rsquo; equity interests in the Company at and after the time that the hedging activities are being
conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction
Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(gg)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Regulation M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly
or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company
to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases
of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other
securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with
the placement of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(hh)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>FDA</U>. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;)
under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured,
packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical
Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by
the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure
to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company&rsquo;s knowledge, threatened,
action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation)
against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice,
warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure,
registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the
labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of,
or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes
a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the
Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or
any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries,
and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the
Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the
FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States
of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or
clearing for marketing any product being developed or proposed to be developed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Stock Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i)
in accordance with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market
value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted
under the Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no
Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with,
the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results
or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(jj)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Cybersecurity</U>. (i)(x) To the knowledge of the Company, there has been no security breach or other compromise of or relating
to any of the Company&rsquo;s or any Subsidiary&rsquo;s information technology and computer systems, networks, hardware, software, data
(including the data of its respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of
it), equipment or technology (collectively, &ldquo;<U>IT Systems and Data</U>&rdquo;) and (y) the Company and the Subsidiaries have not
been notified of, and have no knowledge of any event or condition that would reasonably be expected to result in, any security breach
or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries are presently in compliance in all material respects
with all applicable laws, statutes or regulations, internal policies and contractual obligations relating to the privacy and security
of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification,
except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii)&nbsp;the Company and the Subsidiaries have
implemented and maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity,
continuous operation, redundancy and security of all IT Systems and Data;
and (iv) the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry standards
and practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(kk)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Compliance with Data Privacy Laws</U>. (i)&nbsp;The Company and the Subsidiaries are, and at all times during the last three
(3) years were, in compliance in all material respects with all applicable data privacy and security laws and regulations, including,
without limitation, the European Union General Data Protection Regulation (&ldquo;<U>GDPR</U>&rdquo;) (EU 2016/679) (collectively, &ldquo;<U>Privacy
Laws</U>&rdquo;); (ii)&nbsp;the Company and the Subsidiaries have in place, comply with, and take appropriate steps reasonably designed
to ensure compliance with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure,
handling and analysis of Personal Data (as defined below) (the &ldquo;<U>Policies</U>&rdquo;); (iii)&nbsp;the Company provides accurate
notice of its applicable Policies to its customers, employees, third party vendors and representatives as required by the Privacy Laws;
and (iv)&nbsp;applicable Policies provide accurate and sufficient notice of the Company&rsquo;s then-current privacy practices relating
to its subject matter, and do not contain any material omissions of the Company&rsquo;s then-current privacy practices, as required by
Privacy Laws.&nbsp;&ldquo;<U>Personal Data</U>&rdquo; means personal data as defined by the Privacy Laws. (i)&nbsp;None of such disclosures
made or contained in any of the Policies have been inaccurate, misleading, or deceptive in violation of any Privacy Laws and (ii)&nbsp;the
execution, delivery and performance of the Transaction Documents will not result in a breach of any Privacy Laws or Policies. Neither
the Company nor the Subsidiaries (i)&nbsp;to the knowledge of the Company, has received written notice of any actual or potential liability
of the Company or the Subsidiaries under, or actual or potential violation by the Company or the Subsidiaries of, any of the Privacy Laws;
(ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant
to any regulatory request or demand pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or agreement by or with
any court or arbitrator or governmental or regulatory authority that imposed any obligation or liability under any Privacy Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ll)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(mm)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within
the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(nn)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company
Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
&ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly,
five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total
equity of a bank or any entity that is subject to the
BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence
over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(oo)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering
Laws</U>&rdquo;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving
the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary,
threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Representations and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents
and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which
case they shall be accurate as of such date):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Organization; Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited
liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance
by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate,
partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which
it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will
constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i)
as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Understandings or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this
representation and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or
otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the
ordinary course of its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT> <U>Purchaser Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on
each date on which it exercises any Warrants, it will be either: (i) an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1),
(a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12) or (a)(13) under the Securities Act or (ii) a &ldquo;qualified institutional buyer&rdquo;
as defined in Rule 144A(a) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Experience of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an
investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Access to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded (i) the opportunity to ask such questions as it has deemed
necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities
and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results
of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that neither the
Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect to the
Securities nor is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate has made or makes
any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public
information with respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance
of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary
to such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Certain Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser
has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed
any purchases or sales, including Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that
such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth
the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the
foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions
of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio
managers managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to
the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.
Other than to other Persons <U STYLE="text-decoration: none">party to this Agreement or to such
Purchaser&rsquo;s representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees,
agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction
(including the existence and terms of this transaction).</U> Notwithstanding the foregoing, for the avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to
effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Company acknowledges and
agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s right to rely on
the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties contained in any
other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation
of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute
a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or
similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE IV.</B><BR>
OTHER AGREEMENTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT> <U>Warrant Shares</U>. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement
to cover the issuance or resale of the Warrant Shares or if the Warrant is exercised via cashless exercise, the Warrant Shares issued
pursuant to any such exercise shall be issued free of all legends. If at any time following the date hereof the Registration Statement
(or any subsequent registration statement registering the sale or resale of the Warrant Shares) is not effective or is not otherwise available
for the sale or resale of the Warrant Shares, the Company shall immediately notify the holders of the Warrants in writing that such registration
statement is not then effective and thereafter shall promptly notify such holders when the registration statement is effective again and
available for the sale or resale of the Warrant Shares (it being understood and agreed that the foregoing shall not limit the ability
of the Company to issue, or any Purchaser to sell, any of the Warrant Shares in compliance with applicable federal and state securities
laws). The Company shall use best efforts to keep a registration statement (including the Registration Statement) registering the issuance
or resale of the Warrant Shares effective during the term of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Furnishing of Information</U>. Until the earlier of the time that (i) no Purchaser owns Securities or (ii) the Warrants have
expired, the Company covenants to maintain the registration of the Common Stock under Section 12(b) or 12(b) of the Exchange Act or to
timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by
the Company after the date hereof pursuant to the Exchange Act as long as the Company is then subject to the reporting requirements of
the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3 <U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in
Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules and
regulations of any Trading Market such that it would require shareholder approval prior to the <FONT STYLE="text-decoration: none">closing
of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Securities Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time issue a press release disclosing the
material terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents
as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release,
the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of
the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents in connection
with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company
acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between
the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates on the one hand,
and any of the Purchasers or any of their Affiliates on the other hand, shall terminate. The Company understands and confirms that each
Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and each Purchaser
shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the
Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of
the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press
release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in
which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding
the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with
the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required
by federal securities law in connection with the filing of final Transaction Documents with the Commission and (b) to the extent such
disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice
of such disclosure permitted under this clause (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Shareholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other
Person, that any Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison
pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted
by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving
Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6 <U>Non-Public
Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person
acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company
reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the
receipt of such information and <U STYLE="text-decoration: none">agreed with the Company to keep such information confidential. The Company understands and
confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To
the extent that the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or
Affiliates delivers any material, non-public information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby
covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any
of their respective officers, directors, agents, employees or Affiliates, or a duty to the Company, any of its Subsidiaries or any
of their respective officers, directors, agents, employees or Affiliates not to trade on the basis of, such material, non-public
information, provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant to
any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the
Company shall simultaneously file such material non-public information with the Commission pursuant to a Current Report on Form 8-K.
The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in
securities of the Company.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Use of Proceeds</U>. Except as set forth in the Prospectus Supplement, the Company shall use the net proceeds from the sale
of the Securities hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of any portion of the
Company&rsquo;s debt (other than payment of trade payables in the ordinary course of the Company&rsquo;s business and prior practices),
(b) for the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in
violation of FCPA or OFAC regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.8 <U>Indemnification
of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its
directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such
Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers,
shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding
such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser
Party</U>&rdquo;) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses,
including all judgments, amounts paid in settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation
that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations,
warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action
instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the
Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction
Documents (unless such action is solely based upon a material breach of such Purchaser Party&rsquo;s representations, warranties or
covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such
stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party
which is finally judicially determined to constitute fraud, gross negligence or willful misconduct). If any action shall be brought
against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall
promptly notify the Company in writing, and the Company shall have the right to assume <U STYLE="text-decoration: none">the defense thereof with counsel of its
own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in
any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such
Purchaser Party except to the extent that (x) the employment thereof has been specifically authorized by the Company in writing, (y)
the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (z) in such action there
is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and the
position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more
than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (1) for any settlement by
a Purchaser Party effected without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld or delayed;
or (2) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s
breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the
other Transaction Documents. The indemnification required by this Section 4.8 shall be made by periodic payments of the amount
thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements
contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others
and any liabilities the Company may be subject to pursuant to law.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Reservation of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and
keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the
Company to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Listing of Common Stock</U>. For as long as the Warrants are outstanding and exercisable, the Company hereby agrees to use reasonable
best efforts to maintain the listing or quotation of the Common Stock on the Trading Market on which it is currently listed, and concurrently
with the Closing, the Company shall apply to list or quote all of the Shares and Warrant Shares on such Trading Market and promptly secure
the listing of all of the Shares and Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have
the Common Stock traded on any other Trading Market, it will then include in such application all of the Shares and Warrant Shares, and
will take such other action as is necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading
Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its
Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations under
the bylaws or rules of the Trading Market. For so long as the Company maintains a listing or quotation of the Common Stock on a Trading
Market, the Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company
or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company
or such other established clearing corporation in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>[Reserved].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT> <U>Subsequent Equity Sales</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>From the date hereof until sixty (60) days after the Closing Date (and until thirty (30) days after the Closing Date with respect
to Citius Oncology, Inc.), neither the Company nor any Subsidiary nor Citius Oncology, Inc. shall (i) issue, enter into any agreement
to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration
statement or any amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8
in connection with any employee benefit plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>From the date hereof until the one (1) year anniversary after the Closing Date, the Company shall be prohibited from effecting
or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents
(or a combination of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction
in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or
include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other
price that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the initial
issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some
future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly
or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction
under, any agreement, including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the
Company may issue securities at a future determined price, regardless of whether shares pursuant to such agreement have actually been
issued and regardless of whether such agreement is subsequently canceled; <U>provided</U>, <U>however</U>, that, (y) after thirty (30)
days after the Closing Date, the issuance of shares of Common Stock in an &ldquo;at the market&rdquo; offering with the Placement Agent
as sales agent at an offering price equal to or greater than $1.75 per share, subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement, shall
not be deemed a Variable Rate Transaction and (z) after the prohibition period in Section 4.12(a) above, the entry into and/or issuance
of shares of Common Stock in an &ldquo;at the market&rdquo; offering with the Placement Agent as sales agent shall not be deemed a Variable
Rate Transaction. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which
remedy shall be in addition to any right to collect damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Notwithstanding the foregoing, this Section 4.12 shall not apply in respect of an Exempt Issuance, except that no Variable Rate
Transaction shall be an Exempt Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.13 <U>Equal Treatment
of Purchasers</U>. No consideration (including any modification of this Agreement) shall be offered or paid to any Person to amend
or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also offered to <U STYLE="text-decoration: none">all of
the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by
the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and
shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or
voting of Securities or otherwise. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Certain Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants
that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such
time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described
in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions
contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4,
such Purchaser will maintain the confidentiality of the existence and terms of this transaction (other than as disclosed to its legal
and other representatives). Notwithstanding the foregoing, and notwithstanding anything contained in this Agreement to the contrary,
the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will
not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement
are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be restricted
or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and
after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release
as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the
Company to the Company or its Subsidiaries, or any of their respective officers, directors, employees, Affiliates, or agents, including,
without limitation, the Placement Agent, after the issuance of the initial press release as described in Section 4.4. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate
portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the
portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect
to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Exercise Procedures</U>. The form of Notice of Exercise included in the Warrants sets forth the totality of the procedures required
of the Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required
of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required,
nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to
exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms,
conditions and time periods set forth in the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Termination</U>. This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder
only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other
parties, if the Closing has not been consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>,
<U>however</U>, that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>Fees and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the
fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees
(including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise
notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the
Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus
Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior
agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such
documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall
be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication
is delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New
York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered
via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>)Trading Day following the date of mailing, if sent
by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be
given. The address for such notices and communications shall be as set forth on the signature pages attached hereto. To the extent that
any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company
or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5 <U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed,
in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares and Pre-Funded
Warrants based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the
case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, <U STYLE="text-decoration: none">modification
or waiver disproportionately and adversely impacts a Purchaser (or at least 50.1% in interest of such group of Purchasers), the
consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with
respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a
waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or
omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or
waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to the
comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected
Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities
and the Company.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed
to limit or affect any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors
and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Securities, provided that such transfer is in compliance with all applicable federal and state
securities laws and such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the
Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations, warranties,
and covenants of the Company in this Agreement and the representations, warranties, and covenants of the Purchasers in this Agreement.
This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for
the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section
5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.9 <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be
governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party
hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect
to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or
Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is
improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably <U STYLE="text-decoration: none">waives personal service of process and
consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or
overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and
agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall
be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action
or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under
Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable
attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or
Proceeding.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities
for a period of not longer than six (6) years from the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery
of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by
such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.13 <U>Rescission and
Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of
the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document
and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind
or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in
whole or in part without prejudice to its future actions and rights; provided, however, that in the case of a rescission of an
exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded
exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares
and the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such <U STYLE="text-decoration: none">Purchaser&rsquo;s Warrant (including,
issuance of a replacement warrant certificate evidencing such restored right).</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Replacement of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of
damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties
agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in
the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the
defense that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.16<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Payment Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction
Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement
or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged
by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law
(including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent
of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force
and effect as if such payment had not been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.17 <U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or
non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers
as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in
any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other
Purchaser to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own
separate legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only,
each Purchaser and its respective counsel have chosen to communicate with the Company through EGS. EGS does not represent any of the
Purchasers and only represents the Placement Agent. The Company has <U STYLE="text-decoration: none">elected to provide all Purchasers with the same terms and
Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the
Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction
Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between
and among the Purchasers.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.18<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Liquidated Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the
Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and
other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages
or other amounts are due and payable shall have been canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.19<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Saturdays, Sundays, Holidays, etc.</U> If the last or appointed day for the taking of any action or the expiration of any
right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next
succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.20<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to
revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved
against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition,
each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the
date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.21<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><B><U>WAIVER OF JURY TRIAL</U>. <U STYLE="text-decoration: none">IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER
PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the
date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="4"><FONT STYLE="text-transform: uppercase"><B>Citius Pharmaceuticals, Inc.</B></FONT></TD>
    <TD COLSPAN="2"><U>Address for Notice:</U></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 4%">&nbsp;</TD><TD STYLE="text-align: left; width: 5%">&nbsp;</TD>
    <TD STYLE="width: 31%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD><TD STYLE="text-align: justify; width: 35%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>By:</TD><TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: left"></TD>
    <TD>&nbsp;</TD>
    <TD>E-mail:&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD STYLE="text-align: left">Name:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD STYLE="text-align: left">Title:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[PURCHASER SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">ctxr</FONT>
SECURITIES PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Purchaser: ______________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Purchaser</I>:
_________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: _______________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email Address of Authorized Signatory:_________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice to Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Delivery of Warrants to Purchaser (if not same as address
for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subscription Amount: $_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pre-Funded Warrant Shares: ___________ Beneficial Ownership Blocker
<FONT STYLE="font-family: Wingdings">o</FONT> 4.99% or <FONT STYLE="font-family: Wingdings">o</FONT> 9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Common Warrant Shares: __________________ Beneficial Ownership Blocker
<FONT STYLE="font-family: Wingdings">o</FONT> 4.99% or <FONT STYLE="font-family: Wingdings">o</FONT> 9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EIN Number: ____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744; Notwithstanding anything contained
in this Agreement to the contrary, by checking this box (i) the obligations of the above-signed to purchase the securities set forth
in this Agreement to be purchased from the Company by the above-signed, and the obligations of the Company to sell such securities
to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii) the Closing shall occur by the
first (1st) Trading Day following the date of this Agreement and (iii) any condition to Closing contemplated by this Agreement (but
prior to being disregarded by clause (i) above) that required delivery by the Company or the above-signed of any agreement,
instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall instead be an
unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument, certificate or
the like or purchase price (as applicable) to such other party on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">37</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>7
<FILENAME>ea024524101ex99-1_citius.htm
<DESCRIPTION>PRESS RELEASE, DATED JUNE 10, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;<IMG SRC="ex99-1_001.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Citius Pharmaceuticals Announces a Registered
Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>$6 million upfront with up to an additional
$9.8 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cranford, NJ, June 10,
2025</B>&nbsp;&ndash; Citius Pharmaceuticals Inc. (Nasdaq: CTXR) (&ldquo;Citius Pharma&rdquo; or the &ldquo;Company&rdquo;), a
biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today
announced that it has entered into definitive agreements for the purchase of an aggregate of 4,920,000 shares of its common stock
(or pre-funded warrant in lieu thereof) and accompanying short-term warrants to purchase up to an aggregate of 9,840,000 shares of
its common stock, at a purchase price of $1.22 per share (or pre-funded warrant in lieu thereof) and accompanying short-term warrant
in a registered direct offering priced at-the-market under Nasdaq rules. The short-term warrants will have an exercise price of
$1.00 per share, will be exercisable immediately upon issuance, and will expire twenty-four months from the initial exercise date.
The closing of the offering is expected to occur on or about June 11, 2025, subject to the satisfaction of customary closing
conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">H.C. Wainwright &amp; Co. is acting as the exclusive
placement agent for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate gross proceeds to the Company from
the offering are expected to be approximately $6 million, before deducting the placement agent fees and other offering expenses payable
by the Company. The potential additional gross proceeds to the Company from the short-term warrants, if fully-exercised on a cash basis,
will be approximately $9.8 million. No assurance can be given that any of such short-term warrants will be exercised. The Company currently
intends to use the net proceeds from the offering to support the commercial launch of LYMPHIR&trade;, including milestone, regulatory
and other payments, as well as for general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities described above are being offered
pursuant to a &ldquo;shelf&rdquo; registration statement (File No. 333-277319) filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;)
on February 23, 2024 and declared effective on March 1, 2024. The offering is being made only by means of a prospectus, including a prospectus
supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating
to the securities being offered will be filed with the SEC and be available at the SEC&rsquo;s website at www.sec.gov. Electronic copies
of the prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained, when available,
by contacting H.C. Wainwright &amp; Co., LLC at 430 Park Avenue, 3<SUP>rd</SUP>&nbsp;Floor, New York, NY 10022, by telephone at (212)
856-5711 or e-mail at placements@hcwco.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release shall not constitute an offer
to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under
the securities laws of any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Citius Pharmaceuticals, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Citius Pharma is a biopharmaceutical company dedicated
to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted
immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma&rsquo;s late-stage pipeline also
includes Mino-Lok<SUP>&reg;</SUP>, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections,
and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial
for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged
with the FDA to outline next steps for both programs. Citius Pharma owns 92% of Citius Oncology, Inc. (&ldquo;Citius Oncology&rdquo;).
For more information, please visit www.citiuspharma.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward Looking Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release may contain &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these
statements by the fact that they use words such as &ldquo;will,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
&ldquo;plan,&rdquo; &ldquo;should,&rdquo; and &ldquo;may&rdquo; and other words and terms of similar meaning or use of future dates. Forward-looking
statements are based on management&rsquo;s current expectations and are subject to risks and uncertainties that could negatively affect
our business, operating results, financial condition and stock price, and includes all statements related to the completion of the offering,
the satisfaction of customary closing conditions related to the offering, the exercise of the short-term warrants prior to their expiration
and the intended use of net proceeds from the offering. Factors that could cause actual results to differ materially from those currently
anticipated, and, unless noted otherwise, that apply to Citius Pharma and Citius Oncology, are: related to the closing of the offering;
our need for substantial additional funds; our ability to raise additional money to fund our operations for at least the next 12 months
as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; Citius
Pharma&rsquo;s ability to regain compliance with Nasdaq&rsquo;s continued listing requirements; risks relating to the results of research
and development activities, including those from our existing and any new pipeline assets; risks related to research using our assets
but conducted by third parties; the estimated markets for our product candidates and the acceptance thereof by any market; the ability
of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our
ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements
and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and
other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close
and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other
risks described in our SEC filings. These risks have been and may be further impacted by any future public health risks. Accordingly,
these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance
on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the
SEC&rsquo;s website at www.sec.gov, including in Citius Pharma&rsquo;s Annual Report on Form 10-K for the year ended September 30, 2024,
filed with the SEC on December 27, 2024, as amended on January 27, 2025, as updated by our subsequent filings with the SEC. These forward-looking
statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions
or circumstances on which any such statement is based, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ilanit Allen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ir@citiuspharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">908-967-6677 x113</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STiR-communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Greg Salsburg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Greg@STiR-communications.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>8
<FILENAME>ea024524101ex99-2_citius.htm
<DESCRIPTION>PRESS RELEASE, DATED JUNE 12, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Citius Pharmaceuticals Announces Closing of
Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>$6 million upfront with up to an additional
$9.8 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cranford, NJ, June 12, 2025</B>&nbsp;&ndash;
Citius Pharmaceuticals Inc. (Nasdaq: CTXR) (&ldquo;Citius Pharma&rdquo; or the &ldquo;Company&rdquo;), a biopharmaceutical company dedicated
to the development and commercialization of first-in-class critical care products, today announced the closing of its previously announced
registered direct offering priced at-the-market under Nasdaq rules for the purchase of an aggregate of 4,920,000 shares of its common
stock (or pre-funded warrants in lieu thereof) and accompanying short-term warrants to purchase up to an aggregate of 9,840,000 shares
of its common stock, at a purchase price of $1.22 per share (or pre-funded warrant in lieu thereof) and accompanying short-term warrant.
The short-term warrants have an exercise price of $1.00 per share, are exercisable immediately upon issuance, and will expire twenty-four
months from the initial exercise date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">H.C. Wainwright &amp; Co. acted as the exclusive
placement agent for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate gross proceeds to the Company from
the offering were approximately $6 million, before deducting the placement agent fees and other offering expenses payable by the Company.
The potential additional gross proceeds to the Company from the short-term warrants, if fully-exercised on a cash basis, will be approximately
$9.8 million. No assurance can be given that any of such short-term warrants will be exercised. The Company currently intends to use the
net proceeds from the offering to support the commercial launch of LYMPHIR&trade;, including milestone, regulatory and other payments,
as well as for general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities described above were offered pursuant
to a &ldquo;shelf&rdquo; registration statement (File No. 333-277319) filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;)
on February 23, 2024 and declared effective on March 1, 2024. The offering was made only by means of a prospectus, including a prospectus
supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating
to the securities being offered was filed with the SEC and is available at the SEC&rsquo;s website at www.sec.gov. Electronic copies of
the prospectus supplement and the accompanying prospectus relating to the securities offered may also be obtained by contacting H.C. Wainwright
&amp; Co., LLC at 430 Park Avenue, 3<SUP>rd</SUP>&nbsp;Floor, New York, NY 10022, by telephone at (212) 856-5711 or e-mail at placements@hcwco.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release shall not constitute an offer
to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under
the securities laws of any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Citius Pharmaceuticals, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Citius Pharma is a biopharmaceutical company dedicated
to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted
immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma&rsquo;s late-stage pipeline also
includes Mino-Lok<SUP>&reg;</SUP>, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections,
and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial
for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged
with the FDA to outline next steps for both programs. Citius Pharma owns 92% of Citius Oncology, Inc. (&ldquo;Citius Oncology&rdquo;).
For more information, please visit www.citiuspharma.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward Looking Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release may contain &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these
statements by the fact that they use words such as &ldquo;will,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
&ldquo;plan,&rdquo; &ldquo;should,&rdquo; and &ldquo;may&rdquo; and other words and terms of similar meaning or use of future dates. Forward-looking
statements are based on management&rsquo;s current expectations and are subject to risks and uncertainties that could negatively affect
our business, operating results, financial condition and stock price, and includes all statements related to the exercise of the short-term
warrants prior to their expiration and the intended use of net proceeds from the offering. Factors that could cause actual results to
differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma and Citius Oncology, are:
our need for substantial additional funds; our ability to raise additional money to fund our operations for at least the next 12 months
as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; Citius
Pharma&rsquo;s ability to regain compliance with Nasdaq&rsquo;s continued listing requirements; risks relating to the results of research
and development activities, including those from our existing and any new pipeline assets; risks related to research using our assets
but conducted by third parties; the estimated markets for our product candidates and the acceptance thereof by any market; the ability
of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our
ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements
and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and
other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close
and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other
risks described in our SEC filings. These risks have been and may be further impacted by any future public health risks. Accordingly,
these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance
on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the
SEC&rsquo;s website at www.sec.gov, including in Citius Pharma&rsquo;s Annual Report on Form 10-K for the year ended September 30, 2024,
filed with the SEC on December 27, 2024, as amended on January 27, 2025, as updated by our subsequent filings with the SEC. These forward-looking
statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions
or circumstances on which any such statement is based, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ilanit Allen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ir@citiuspharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">908-967-6677 x113</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STiR-communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Greg Salsburg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Greg@STiR-communications.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !9 2P# 2(  A$! Q$!_\0
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MRF(P5#?=/MCBO;[6YBO+2&ZA;=%,@D0^H(R*^=;6RFU,WTL0RT$+7+J!_"&
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MZ#T]JYG7OASXMN_C(^LP:.[Z<VIQ7 G\Z,#RPRDG[V>@/'6I*/HFOE3X]?\
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M"_BSXREAM=7BOY(4;(-]<*D2'^]C/)]P":][^'W@FW\">&4TV.437,C>==3
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M;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>ctxr-20250609.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qRZo7xRiXhun8uNbXQsSa2MmaPtypR1GYkxs2t8HZl6HyAs+F4j6C9+1JBmQaQH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:CTXR="http://citiuspharma.com/20250609" elementFormDefault="qualified" targetNamespace="http://citiuspharma.com/20250609">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://citiuspharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="ctxr-20250609_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ctxr-20250609_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>ctxr-20250609_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>ctxr-20250609_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://citiuspharma.com/role/Cover" xlink:href="ctxr-20250609.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://citiuspharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !9 2P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@"O>WD=A:M<S*YB3ERB[MJ]V(ZX'
M?%2PS17$*302)+%(H9'1LA@>A!'6FW+RQ6TCP1>=(HRL>[;N]L^M>;SZA-X:
MWZ_X<S<Z#)(1?Z:WRFTDS\Q ZH<]1TS[$8I1N9RGR[GIM%9FAZ_I_B&P6[T^
M8.O\:'AXSZ,.U:=)JVY:::N@HHHI#"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA/&6
MDWVDW,GBC0E!DV;=1M"NZ.YC'\3+W('7V^ASW=%-.S)G'F5CP"*\_LN[77O#
M,SP0$XEMF.XVY/\  W]Y#V/X<$5S]V?BCK^IRMHVM:Q>Q@;S]GNA (\]BJE1
MV[#!_,57T[Q##J6HWMQ:1QP.)7W0)RAC+'&!_=Q@8['ZBO4?A3;2-JM[=H0+
M<0>6RYY#%@1^@-=4U&4.8XJ3E"IR?UZD/P@;X@'5-2B\6R:@+*&%1$E['RTC
M'JKD9( 4YYQR*XS7_'WBFU^-#Z5!K5PE@NJ10"W&W;L+*",8]":^CZ^3?$__
M "7^7_L-0_\ H:5R'<>N?%2?XC1:W9#P:MV;(VW[[R(T8>9N/7<,],5Y%J_Q
M$^)V@WYL=5U>[M+H*&,4D,6<'H?NU]9U\J?'K_DITW_7K#_(T =!I5]\;)=2
ML6G&I&U::,R%H8@I0D9SQTQ6W\=?%_B#PWK&DP:/JD]G%+;N\BQ8&XAL9Z5[
M18_\@^V_ZY+_ "%?/?[2'_(P:)_UZO\ ^AT >JVNM:B_P4.MM=,=2&AO<_:,
M#/FB$L&QC'49Z5Y_\#/&7B+Q'XFU*UUC5I[R".S\Q$EP=K;U&>GH378V?_)N
M[?\ 8MR?^B&KS+]G+_D<=5_[!_\ [42@9[=\0=1N])\ ZU?V$[074%N6CD4#
M*G(YYKSKX$>+=>\2W>MQ:SJ<UZD$<31"7'RDEL]O85WGQ2_Y)CX@_P"O4_S%
M>4_LV?\ (0\0_P#7*#^;T 6?BG\7=:M/$DOAKPN_D- PBFN$0/))(<?(F<XQ
MG'3.?3OBIIWQSM$%\'U9@1G:;J*0^O\ JRQ/X8K!^)FF:KX/^*MQK'DD++>C
M4+.=ERCG<'Q^#<$?T(KUCPO\??#NK&.WUJ&72;EN#(Q\R G_ 'AROXC ]:8C
MN_!$^M77@S3+CQ%N&JRQEYPT0C(RQ*@J ,';MR/7-<G\5=<U32;C3(]/OIK9
M94D+^4VW=@KC^=>DPS17,$<\$J2PR*&21&#*RGD$$=17D_QF_P"/S2/^N<O\
MUJZ6LC'$-JF[&%#>>/O[+75XKK4Y+/!82B3>,#()*Y/'!ZBNO\ ?$&ZUB_72
M-7*/<.I,,ZJ%+D#)5@.,X!Y&.E;O@JZMK+X=:=<7<R10)$Y=W. !O:O)O""_
M:/'^GFT7:ANBZKCH@R3^E;:2336QSZTW%I[G4?$/Q-K6E^*WM;'49H(!"A"(
M1C)'->H:1+)<:+832L6DDMXV9CW)4$FO&?BE_P CK)_UPC_E73:=\5M*L],M
M+5["]9H84C8C;@D*!Z^U3*#<%9%0J*-27,S#\9>*]=L/%VH6MIJ<\4$;J$12
M,#Y0:]IKYO\ $NJQ:WXAO-1@C>..=@55\9&% YQ]*^D"<#)Z4JJLD5AY<TI:
MGF/Q)\5ZAINKVVGZ9>/;E(O,F,?4ECP#] ,_C5_X9^)+S6(;ZTU"Y:>>(K(C
M.>2IX(_ @?\ ?5<?IB+XQ^)K32KOMGG:4@_\\T'R@_DH_&F^$YG\-?$-;24X
M7SGLY">X)P#^84UHX+DY>IDJDO:<_1NQ[+JTKP:-?31,5DCMY&5AV(4D&O$M
M/UKQ?K5X;>QU&^FGVERB3;>!CGJ!7M6N?\@#4O\ KUE_]!->2_"S_D;G_P"O
M5_YK44M(MFM>[G&-]Q+;QOXI\.ZC]GU-I)MF-]O=+AL>H;K^/(^M>P:;?P:I
MIUO?6Y)BG0.N>H]C[CI7D?Q.U6QU'7;>.S=)6MHBDLB<@DG.W/?']:](\%64
MVG^#]-M[A2LHC+E3U&YBP!_ BBJERJ5K,*+:FX7ND>4MXXUZ#5VE&HS/"DY;
MRF(P5#?=/MCBO;[6YBO+2&ZA;=%,@D0^H(R*^=;6RFU,WTL0RT$+7+J!_"&
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MZ#T]JYG7OASXMN_C(^LP:.[Z<VIQ7 G\Z,#RPRDG[V>@/'6I*/HFOE3X]?\
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M"_BSXREAM=7BOY(4;(-]<*D2'^]C/)]P":][^'W@FW\">&4TV.437,C>==3
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M;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 09, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  09,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Citius Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001506251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3425913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11 Commerce Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">1st Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cranford<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">967-6677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CTXR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0245241-8k_citius.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://citiuspharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ctxr-20250609.xsd</File>
    <File>ctxr-20250609_lab.xml</File>
    <File>ctxr-20250609_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0245241-8k_citius.htm">ea0245241-8k_citius.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>21
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0245241-8k_citius.htm": {
   "nsprefix": "CTXR",
   "nsuri": "http://citiuspharma.com/20250609",
   "dts": {
    "schema": {
     "local": [
      "ctxr-20250609.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ctxr-20250609_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ctxr-20250609_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0245241-8k_citius.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://citiuspharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-09",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245241-8k_citius.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-09",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245241-8k_citius.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0001213900-25-053607-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-053607-xbrl.zip
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MU]\&1KMEYDU-:M(T*#0@SM[B%R#P4 6JU?&A-F/YO)BG'AI7V=QX]+1XQ/(
MWFZS5,V@TAA\%;PSR/'MA0$-,&XR=$0$A-X F] -ASP2Y:$?4!&,:M&>SL_2
M0Q9 $G_>WY,'(M1[!TNRRS[+'3UUG&$,B'5]]C:X.>;)7&]@$!"^U2UTJI>B
M>@5HI9X1*ZM OZM*4%Z+[??+ZYNNY2>Y66^2?ZUP2N26_P)02P,$%     @
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M&[@2GMORHZ.(@X,4UR_8!LR5^,!W+3. OSSF>'UJFW=R50*TWS<AV01GP$%
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M2]Q0$7=?8F,#]\#-*-VKFFFZ@"[A$3;(;P@X+QD>[ 31"D\87'XA4A0Z4'_
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M'L2CIES!)6>K1H?U:%HVH"&^B[["SZ:D0=UG/X!>_A2='C^%,==H$?WEN9^
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M_,3C0RI"4A&/#ZF(/]7A?T^!F,^F^(J'=>J_]#S#[#*B%"9:D8KO,51IYYN
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M/W[\Z.SKKQ^??BOF&-\ S4$ZL);WBCR F,B3O*FFY16A#]&M$&98F$"6F)B
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M%6CM&Q/YHP+A F#PZBNNE^[?'4?'#V*"'\(8_"(;QG(0>$19WI.%9D:G=JM
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MY[M1<UQ7/3Q-J9R/Q@Y/@=7'38(R:)(=$3MZR]UP'@F?+*Q9AJG30RE)H+2
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MG[[,4^IIII;PV;IB8))D%QB$C!(96[>V$%Z1=)]@!RIQE$]9OT!F?RXX5.9
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MSFNDU)@&.AX?GXG[_*!4_(Y@_->'8+P&X[\^!.,_7U?</T?-Y'_NUY"%C8D
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MC"8QGK:<BZ!6PS6=H=I.C/PS#HARDJNLZ"NRIHQ%']6.IOZ$8'P@*G)>%$A
MS//A.17A9,.G%+%C1D/,*JX:YO![?!)'9R=G3X^C=SZN1 P\=4TX?O283,F
M\O -3* K_3! )C7Q6Y0A[D7'HSX2]0YD+_9(1)DJ[UQN"!I(].QFA&WNBK5
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MAJAK8NEK$'U*TY56/: KS8&/2DL4AIHS"^W88'?FG1V 39?>52KN)MTIY6K
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M2&&&%4TRPAVPE!S!>^9Y>6T>2&8++.K,(3">\*#J.$M8P;+M)>)5CHE^$5^
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MO6BR4(3(1,4?@/+:^\& NN&J.28[GHJP;&./B4.:^*W%RYFD/VP7F+J*IP@
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M7\/1IW;%>%RPVXHN.@=OJ/QO86K.5 0B5GXG,Z[?!-1*"C\1@(%IC*!(R"3
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MF. 53^/C6 5%(EUE&UDCA<38_*)CG?+J#B)K2H.Y"9;!=:TUEQ/3]<KD8)D
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MXYPJ7$D1J-X: X[IR?_KF)ZW_J<FBR7(O9.7I_\DM.2/YS\]/_K_4$L#!!0
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M RL GB.GV6>P*+F&4T][8>Q#HW/UI7BOL5)%UWP6Z9=-KI!-5,SGV'N]M5Z
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M@XE)(XMUW2<626#^9&1%;"W79HDHR!$LZ%:S!&[(O_DYAZ!2SZQ!IGP=*@L
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MVD&'A=MV(NRF#3'H,$%DHP022[C=: Q7AQ-X"N'+K&,Q%NXS;C(7!H%8D5O
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MOE)?31?WQQ6\I6!>@4V3U4C@2:Z2BC(+[G +L4G(K)16!]/!,.I9,TGXJBS
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M)8UW697Y?CB@E75P=$2F< "-A8$!RZW4MG\D-WK3!T?%!V_7V;\5/UV/#!9
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M^5BR >? 6@1LJN];6QS*F  6'*1TA8/90FI#W6/9CNWGU.G0OO3W>KA]MG?
M;R(-EB2L9C[._QOV,^SC\J%DX./@&>UG4C#1D$OA3O GZI 5_+IQZ->+:^YM
MXIJMN.;>)J[YC3"XQHS_BW/^'00.V+C:H":#_5MH\X<"#B8)I?N@0&MB@]%$
MF3YY#'I6X" VX12917P$2Z>22A?RR_C^Z%/B/^6V[5I($[R@QR @+#CKQ@T_
M;R3U@_3[>UF]LS:^!8MSRKES:5PNBRD(33)2Z79:' X')PG5*A/R."(;.JXY
M&3=H>$IHM$,QGQ)=2F$K6K%JM*ST+R%)1-$08 !7N2C$P,0XT +LFZC.&%]
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M?#&J0Z,31&DR T>L-KA9_=%[;$CTL5Q8'%)HE$+#1I[[G8R82--H.B&9K!,
M8QS=@H>9:"=XN[=)?'?F)5!>LK_S.962*=<AB*W\]QMHR&S--=(_92?XG4 ]
M+YRF"[&SV="UK,):TFSUU$X2#+*(9=B-D%@OOO-H$]]IQ7<>;>([WPB#7WF8
ME@9<53"T)2E*_HII'D #?5&(PUUSP3'Y09G2G4FFC,(39&ZC_AI]^AJR#R36
MB;&#;.N:,\G"UOIBR;[QB^,NX-<V^G<QISR+1AIB$QX61*F@27E94(&0=0#1
M ,AXTAQY5;%V["P8M^GE;:*]/2K@4.B7'%<T'>IY5M5-]#PO<=;P$2@]8' P
M W%7_P*+5<MH]P^[>S_%T0&V9N)BGD3/#O?_DLPR%1V"M;" MWX'/[W*U'0X
M>)X52<&#7+EHY]G#P_U88U?RTN@&OXWU;__O!"BUJ.=@OLZ2'=A _HGVXGE?
MVVAGK5N2V6-0S_RD!288I)74B0U(*Q52V6^?$G;8B3X5GQFOS(599T;[2(:Y
M.[]@>18QC/'"/78AV#J+-4>)X?4)KRU"?0-"G',0B\9E^4['-TV&F>EL@:T"
MY&U1-T ^"03HP3^IBT$F/E!2X7"+1N/+4ZH>Q!6W]V%<30">8@.>;]?DKR:K
MG?W!>$T(I35,/.<"H9E)YDM<U &--0U./SYYO!O-=V8[T98-AU%Y'+P 87>2
MQ4_]!V:>*!6[.K@ 47>B0O"U#9349WKOJ/W:U"J5)DO!@I. 8N*]"]PN=Z;V
MK44?Y_=Z%"F%H7%,1^K=W4Y6(D;5Y)*('5-*#MS;G?.==65T9$0T O3A4$T>
M\L0]G*U^'X[=$'!G.?,W)JLCMUU+3YQ:&X7-GI][PU^K[QMX+1+<-6P2[@"O
M;3R#3#>G&:N%Y-R+S(4MPOB!]7QUFEZR+M1@; NJ$E#FM/77!AW0=P-[H>PP
M4JZ++DUGM]LKAGV)("7T%#0-9CCUZI_0_\^N@4TN+9JC=K:9I? ,P.4,K,I#
ME.1E_>O=#FU:%0W?L6_:&2N[N@TU-D-#B'_M0[-:\BC=NLR2L+TG<'XS\,F[
M&G'#O[^9<"B[_9U0*/&I'J7)4A!%41!9T<'BDIX3"?*[T0\4W)1(P5 :1W4D
MKMD"&!7\I FPC5]W: ,7MY:-N_D38#;%$,3\5"GWT7TP*4AZU#\8LE)%S6=D
M*F(66RO1;K"!&0[X<%,R>JS DICJ,@7 *T8D.7E"O;Z28WTZ/1/9W""9$9+S
MY:"8*5HB$UN(Y-5FLD+B4 YY(UB;SF_KO.F&^_??Z78M/;VIYNCO 6$J2?#7
M0:=QROU;D?2XN\6.5*5TCU.99T?Y"1\(]E<A\6,24C+:B<4E[=S8X&.+K6VF
M2O(C;&Z-0:$Z4.AZ6>O\SHPJN[B%FRLN6BA28R5IP>^]P=*HA39<R&IP&LGN
M<:E^!ZS.J@H_.;-A[OU<=YEA<3K6CX0@%*4F<%:F#%6'\F[&>ZFUM]UZR9Q+
M7;TQ'368E.3L^YA.&&JS,3,M==1U&][R5R0QIB'FH' R APDU=*;-W$#&U(X
MY,!?2<X]T8$2ZZSCIE YEJA0OY$IAI.V:&04T#H/ATNNLG$F&I]2#RON;HI&
MY+;..]@5MOHY=,A#/TFB%?(<*BK3$43Y+'$F(B-&4NJDTEQY5CG74%U KZS;
M\.Y^(;S[BR(OWK47K^0C+*WO(I"CFM!ZP102L3U'4R#Y'T7N3FT$2R@V)IC$
M$6,G"I68).I_[BZ%<C8/]O]/X+][?N2S4_-JI_OW_ZRM<\+$18.(4C3/*514
MCS[/TS_GFWI/695@?+Q),+82C(^_MP3CYV18_;\[2;_35]&OIQ>O3L[/HU]_
M.7ES\OJY%Y4<#A"[E\;RM)![Q4!Q4*F=?G2N55P4&KS:[>#W87BGE&3CCCCT
MEK +\Q,BTWXHDL+%P>&+D^CHY,6+\[.#H]-7?_[3@]T'].^S@^-C_>\[K^TF
M2YLKO'3W=^9<8XU(,J^!L_7?'A!;/KMXHQ^ 0Y\0[E._!W#] \VZ%\=F[?!7
M\V%T]!J7_NI/#QX#OSU__>K"7>WV-)EE^?+)6M*!6UQ!I#P!1Q9<3P25@GL>
M[A]1=C(ZH_3D1"UHC?#CTV*R@YG*9P_QN?NT,/B_-Y_ZM9P+/M'M]P^73_H>
M^,CL]QH"^</6I*\2-OEI]W</PE3PK_MAO<M^A,M((J]Q[>,]<\__C/__I%P2
M_/ " Z%/^J^T#W](TN6+"KA;+)<?-I9+RW+YX?NV7+Z\!P7ZYM7KB].CD^CU
M\^CD;R=OCD[/3UC+W*>ML,(R<"V!MJ7P@2M9R;F>^0 $62G#>EX&7Z MZW=W
M'G'1I&LEK-#\%^433[/WW-!?0:ZFS8/.#X)K7'<=/>;'<,#VAUTAO#3*WON7
MNU\$Y)FD^]8>QGDN,/Y&$3Q!])=LA<(BY-I+./^/_->!XVU!"3NE!2W<$&7G
MU.A[;%$\*)M:@#FJW<&*<X$2I;2#5!12/%JC",DM36J2,\]F/$AK'D*>NR%*
M?Y*-GHC^Y9V(S[?[CW#WSYB4PP$'XPCY0P!,:-3\%NP5 J59PHW+]Z,G7VK2
M\Y>?-4TK^-\__^$','>R8CC(DQO@-LH[F]*(MP4%R:GGN'X:E=6&7$2N*67Y
M)0O).$ !1.#^:>DUE:]I9(NXKP$<>7>1)WY1'-90*4&0>[0U&<7]-39T(PW<
M)3)LEKS/9HM9_^)$2+9&8\@(@7:/%\U#G:@4 Y\]JXQPD=^3.'I,X@AG) -Y
M&!:(IMUT$>*H'M.95^$J+VZ(<2J=Z4+F'#NK:ZSR\N;3";&O2*^S<?T_J__[
M$DOZ',1@9-$6PSA5S;K:5HZE*4P=#HY_/3B*#D"6(++6*SKC&_;X3V./#3&^
M;F)\+B&QKJ_XC_/3/[\ZN'C[YF0X>/T\^N7UB^.3-_\T3N)_YC0@#O>B:CUE
M/(+B,CK!@LWED^@6[EC[OWO?X--]FUB&-[$0W!%_7G)EJGG#X8!?$5-K'_":
MGVM'0N_Q27;EWM4RC2^ZSS>X]U?  7N?[@1\[M5_)L&Z3H'#CY\K.>#%P"T!
M[C/L_L'IA9[E?:9 /14P4[1<K^/>(N3V42=_^^7T\/0B.OP"\?A[RC9T,N8W
M"E]79Z@>[!^<HTGQ\@0N>_[ZS<O[-2767Y:FSA<S;+ 4[**4PG0=PV$ 90>7
M1,]NI6 -#STG**SY/%_:'CZGK6XG.BZITV)1N[]R0]H\Z6'G/BO.>@SN791:
M7W+"(W!@]->#%V]/HC<G1R>G?STYCGM(;_JVI=/!=C8TNL6E4J;;Q<SL+K\&
M@GY+13GM$HV??Q?*AU&:>64AQJ-;:CO"6E3K4/-R/<__R#J5[@W7+I?HO\46
M!PX19;EH1E_C"C^JHJ3_M@>" 7&'M=VV^_>ZXQV-_$$D-7>YMWW_Q.O\Y+MO
M[GQV51;*ABSOA0L< _\K(/ <&U6+2VN$H]R_Q>[[],L^(?R%>SY^7SGA/Q_9
M60ZA#YZNX83'7Z.D_GIU2 M1T(3.^BG]-;[%-T-?+3/Z^?C3O\0GJ6*ZI= L
MY'M^*N]F\^@U'_UE'^K$J]XL<K6M8U9NG,VO1W2^H-!$G?U;B68114G+"03Z
M-)$Q7";_[X;+O.=_:0YX>/CZ^.]44OC+Q<L7^_\?4$L#!!0    ( *Y%S%HN
MAF<8CT8  ,%[ 0 ;    96$P,C0U,C0Q,#%E>#0M,U]C:71I=7,N:'1M[7U[
M<]M&LN__K.)WP/7=W1)OP;+\2C:V5W7U\D9[_+J6G.S6J5-;(#&4$(, %P E
M<S_][=<\ 9!48MG6AJE*(E$@9J:GIZ?[UZ\7/YZ_?K4_'+SX\>3@&/X?X3\O
MSD_/7YWLOWC _X>_/I _OSA\>_R/Z.S\'Z]._G)O6A;-L^CAWKR)SK.9JJ,W
MZCIZ7\Z2(N8/XNA,5=GT'GP1OOI.?Z]1GYK[29Y=%,^B*KNX;)Y'LZ2ZR(K[
M33E_%NV97\=ETY0S^.3>_HO#_9-/E]DX:Z(GNX]?/#B$V;U;\=Z)*AI5;?#B
M/Q7C>OZ\_;)-%Z??"2^#1V&(]BQH]N]>'1R=O#YY<QX=_!7_>_3V]>NW;V"T
MMT?_%;W[\/[HQX.SD^CG@_?O#]Z<=Z_O\T[IY5N8A4NYIDJ*>EI60)?%?*ZJ
M25(KFKHF$<X)O_4-3>TH:[)%/1R\NTRJ63)1BR:;)#F,=EI,=K_)&?<3\_S@
M\-5)='3RZM79NX.CTS=__<N]O7OT^[N#XV/]^XVG?YVES24^NO?'Y]&XK%)5
MW9^4>9[,:P4KD)_NT=E_<?Y>#W"E*J*E7BJ<H'LB'UZ<'^NGY.5/\=TXI?MU
M]F_%\[JW_W-2 16:Z PV1]7/HG_R/R!6CF_XIM,"]CG)HY-/0,FL5M%QTL ?
M_[8H5/3P81P]VGOTE%X+_WG/*WE Y-S_#%O^39Z57Q9UDTV7\F%6I(I>FA7W
M]L]_/#V+NL7-<- M;Z*=YE)%?\K3?RW*YR\^Z)U[\>##_I\J^G $O X,,<U@
MOLUETL2P255TE>0+%55JHK(KE<9ZA_F?"![(FCI*ZAJF7(=C_%CFP(KN$,-!
M5D>PCJS)\66+>5E$^!TX8C-X39%&]6+\BYHTP(STASR;94W29"6\'9Y5FCOP
M4?S[I"S2C/]\J2J5%<D4WA75JL'9-Y=QE#3P\#)J@.SX!I@Q/3(<X-=38#+Z
M8CD-)]_)D!ZY< [\QGF5P7]ARD^?[>U%\]W9;K2#6_Z/LOH8@0#CX4?XM,O0
MW].8PX$=]!SH &O !;7'&R^:J"@;7'>E:!$QC@D4JR=5-E:T7SBI^:*:7 *[
M1M.JG$4L0*-.^0GD =Z\2M($*%G-RXJ&'@X"6AR5LSD0T9T-;AZ.+HQ0DP"(
M=I+:W<$D12:>P883D1? PSCG+D84$>(S"^P*##T#8IPUY>3C;G0.7S6K ZI/
M8$^G0%;%$XB"+T0T(@P(7*?'@0?S/ )JJ7\M8'N%S\PNO\.7 EGJ*%73K%!I
ME $]SF!!N">/=L8CG(7S/O@QJ^N%(K+7"_R(W@E\A^<IR8KHI+A(+A21X>"B
M4O13'(V7M%ECU5PKQ<= Z$R?_[A[M N#9,4U*5#1GY+9_/EP<%3"IKUZ=103
M[Z8X45CT = B!X%#;/6$II_ **E*=[^H=-K;?8KRZ58UKI4C T/IO7J(O+0;
MP2?'N),L)>@SH&(R![&2P_V3BNQ9U$A,H#N>L!*/V#6R@V8"%B["/)?)E:+]
MFJFDR(J+VLH;X!9_[V$VBPK&AL6^TXQKF, _:.V_V\/&FTW"XP>^#&&3@<\O
M6GS3.$>D@ID!S9*FK)8L-IKR]\L0CPQ#Z--.'WRV6?%_<=BO1YE?-8=DY!*%
MQ*ZC'NQ:X0A_<-F+3;L:M(,YB&Y4E%.4:IZXG25+%+:S) 6I"N?A^K+,%>D-
M131/JB:XH"OZ/][U, VYJFG,SNO8N8+'"LX?G\KP$L4YI2H'_05/0>F=&%A1
M$J6+?(FJQ62!*WAW_!(NP_D2+S)0/N"CX0#>H.[/$I"Q.S"6_)@T33*YQ',Z
MTI1Y4S9R)YEY9BS:49.$Z18P#$L3F$APR[:_[-Z&<!ED0-F"%1>55'D&I$&]
M)1O1#;CS<!2=5TD* @F6S<)@)X,_XO/%8C;FQYU':ECG#&Z..A,Y<M; EY(J
M!=9J0$.C&^L=<%F9TLUN;\1(SM1P\&@G'>$,6$".8)UY7E[K%Y)^!8-:O0TN
M)MRH.LE2U@18213)*MM$?T@N0 Q>X O\RYG4''S UQR&@WJN)JB^IIKFR7R>
M@[(SSCLW!O;T.D.6(44?B5-%H.1? EG_5-5(<Z#/I0(M(JV2ZP+Y+(D^ !O"
M $"H!KATG!2H8^2JKED;A:_C+\.!6?"\*B<J7< XWO2L0C$!Q4X!R5"1N-D*
M=N$S>/#C_1+.(3!\WO$,4$7K.Q4H/+!>('M1:GKC$9BI%'[$R5PL$B2H4L3E
M= E&S7).+[1_@S_!'9E4V;_IB!'OXWNZ2&Q'A4L7'K@&%JZ1R9!!X$O(T!?Z
M<I6C"2H];$FU[& /O)N==^(WYI?+&A7:',]K5:FVPN>?^.%@ >9'[KX;1)D1
M:: #P#ARFGT&BY(K./6T%T:9-3>N?A3?-49U3C, ;>5TD><B_;+));*)BOD<
M>\O;: '$_I.DF"@PZXF'KDDNP#,5[MSCD7_$92U\$O4,2"(Y+$,RWXJL6A]$
MIK$S^F[T#H0V"F*]0!G!F2_0:I$W. &4\4+8FD4MF!@T9YE5 XR46^$T'&Q
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M.G'Q8W=<!B3TU[OOV@ZW[_D6(>=9ZX^/_HQ_!-I'?PF?Z"#7O7TTX(T2_(S
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M;9'DS9(E"!V1/SR,]_;V.D2(LP!/0 P'%ORT$6S]@8D;1[6-8IC,'F%EKDC
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M913!4(CP-F?);@_A%/5"22$\3,'DPX:TP80BL_.UPAL<U7^L+X.3K@2A]JH
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M[5@HSK"QMA L,#S3OE+&:LNZ)C#-C>?A55"];$0Y@TO+J'9T'RM7M\"CDZE
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M6WT\HT*<'@I">9&!5M2%V+92](B09@G#@5:BI?+*/"'HC<_"R,W?U'C9VI0
MUNL,#KTZ)6W'.)E61N^M1'<WXQ(&.\7?9%_&][Y$ZG&)-N:9X E3(<J,TT?D
M':P\V20?*:&///QP&!>%[M,:@I[]1/7K5:\] 9XVLFJ&<5@AIV\E.C[=J77/
MQ& ]QL0-LD:/WX<3WC@0KP*97<[@HNRV?7RUQ'$?W0A@&LG.ZF/2(Y)6G38M
M"G9M/2C?@V6\!7W,Q3S3$@U\V] =0P8N3W6L> )90U7_D8X[=<EF.F,%1>K$
M >NK;CT^9$6\Z'(.L<'44E7E6$]R.1E,S*EAQ ^3!%.)P6["U0GAT<XV_*&H
M.CZ['$F5\\(*#,)@4BKEWKOI9>=7AS58EZZZ7*/VT"/I,!Z9/)O8]B'5E<WT
M$!S"S/XBTN8Z<L^[('X7',2_2U2E64+7SGBW+XN_7.H$HX'B(D]F>EASU/9R
M2!8@/*OLWRI=Y:3#%V3M+B:FK8<T)R-+0P_:KP+1P:C]\WI:9'BW64\1*K#;
M*,Z-HCA_V$9Q;AC%^<,VBO,N'H(I17$>65R&4Z&&@P,RQ.S'KGPWLC%HLF0:
M6B6$#4XDHLG][.&#AWM[&&!I.H%UU:_L" GP!]XP3L0K2"N%1J@ZA!-KQ !:
M(CX"NLX]:,K"4%3@XK=7LNB>QU8@[U^,N)<=UQF%3>-[_!:J$]W%YCW<NL=6
M;2(*^=$?''3]\R6H-U>BFP3A(7"&3"2,WQ!]:;6@-@+155L52_3.&[28NPWW
M,79_GY U31Y11/5R;/+%-0G;%6+#2!9;8L4I4J+CLCAVBLZO3Q%?+H1MQU"U
M]09.HG&%K5ZIH;2+UJ%AHNN0&Y^4'6O+D/O23,HYKP?H:+#["!S@G& , PIJ
M( <)LS8---(%'MNYLHSRP68AQZ'): +,O&)([,Y9-1:U DXPNZRH$$3BT$'T
M#]AD78H?1$0ZQ8[4/=',U@WB#34<& - 7!R)J;=/(:#6[QJ^42?_HH=;"FDP
MR##&9IUC!IC*R@D@[J_\9.+II(A&I2WF2BHB(.@NT#@(@"0W%K5;F">P]=K]
MK3O<XET1X\:+$93<%M^UDY11Z?!D$_;O12!@_"0F 2YCDT[A-6XL5^9$B+N+
MDR+"^-"UP>D2[MS>-LI;\*/0F[5!YY0!@:Z$-H%]!KHJ\P48?)5$HMM?X7@
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MV-M3V?Y.LEC_>3?[FV:%A28SNU*_U&6U+LG5]@4F[K6#9K5X6=I1G275%9_
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MAV^/_X%GY<&/YZ]?[?]_4$L#!!0    ( *Y%S%IB)LTK< L  -,R   ;
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M%DRS3;:QYOBG1,@) +Y0P,C8HUA&(UOQ*+L<B.0 :X ZQ\F\QT2:1GF[8VH
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MI*,%> !X!T'P'Q(;;^!IAV>7R/54-:X1>M&F51.5J6)7%9T[4Q7A G'#WY6
MC .2<1GFC!JM'B^$758^0<!!B2']_OUYQT,'+J4Q#6]<WO+D,%=,Z J6^HIX
MN4M:*0CER<DB3$<S\BQ'S=".KN[F@WL$/X(,<UV!O?54T74R5$,I/( [2IX
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M2"3MQ7-T-;6\.+/;237W<.1=5'>R9J1IL'XU&%SY9LH:Z%$712D$6$5%IUE
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M/U!+ 0(4 Q0    ( *Y%S%I9>F1)+@,  .X+   1              "  0
M  !C='AR+3(P,C4P-C Y+GAS9%!+ 0(4 Q0    ( *Y%S%I>N)WI_0H  '^&
M   5              "  5T#  !C='AR+3(P,C4P-C Y7VQA8BYX;6Q02P$"
M% ,4    " "N1<Q:>AVL@%L'  #<5P  %0              @ &-#@  8W1X
M<BTR,#(U,#8P.5]P<F4N>&UL4$L! A0#%     @ KD7,6M0*G%3=&@  9X\
M !<              ( !&Q8  &5A,#(T-3(T,2TX:U]C:71I=7,N:'1M4$L!
M A0#%     @ KD7,6CZIOEDLG   *U # !P              ( !+3$  &5A
M,#(T-3(T,3 Q97@Q,"TQ7V-I=&EU<RYH=&U02P$"% ,4    " "N1<Q:20K'
M.()&  !L=@$ &P              @ &3S0  96$P,C0U,C0Q,#%E>#0M,5]C
M:71I=7,N:'1M4$L! A0#%     @ KD7,6NFG1+OD0@  QF4! !L
M     ( !3A0! &5A,#(T-3(T,3 Q97@T+3)?8VET:75S+FAT;5!+ 0(4 Q0
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F>#DY+3)?8VET:75S+FAT;5!+!08     "P +  P#  "OR $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>ea0245241-8k_citius_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ctxr-20250609.xsd" xlink:type="simple"/>
    <context id="AsOf2025-06-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506251</identifier>
        </entity>
        <period>
            <startDate>2025-06-09</startDate>
            <endDate>2025-06-09</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-06-09" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-06-09" id="Fact000004">0001506251</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-06-09" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-06-09" id="Fact000010">2025-06-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-06-09" id="Fact000011">Citius Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-06-09" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-06-09" id="Fact000013">001-38174</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-06-09" id="Fact000014">27-3425913</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-06-09" id="Fact000015">11 Commerce Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-06-09" id="Fact000016">1st Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-06-09" id="Fact000017">Cranford</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-06-09" id="Fact000018">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-06-09" id="Fact000019">07016</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-06-09" id="Fact000020">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-06-09" id="Fact000021">967-6677</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-06-09" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-06-09" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-06-09" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-06-09" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-06-09" id="Fact000026">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-06-09" id="Fact000027">CTXR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-06-09" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-06-09" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
